US11478457B2 - Castration-resistant prostate cancer - Google Patents
Castration-resistant prostate cancer Download PDFInfo
- Publication number
- US11478457B2 US11478457B2 US15/136,419 US201615136419A US11478457B2 US 11478457 B2 US11478457 B2 US 11478457B2 US 201615136419 A US201615136419 A US 201615136419A US 11478457 B2 US11478457 B2 US 11478457B2
- Authority
- US
- United States
- Prior art keywords
- compound
- prostate cancer
- pharmaceutically acceptable
- acceptable salt
- udp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- PYZJFRNVKPZAAR-UHFFFAOYSA-N CCC(C)(O)c1nnn(-c2nonc2N)c1C(C)(O)CC Chemical compound CCC(C)(O)c1nnn(-c2nonc2N)c1C(C)(O)CC PYZJFRNVKPZAAR-UHFFFAOYSA-N 0.000 description 3
- ADIPPCCQUCTDJD-UHFFFAOYSA-N O=C(O)CCc1ccc(-c2cccs2)o1 Chemical compound O=C(O)CCc1ccc(-c2cccs2)o1 ADIPPCCQUCTDJD-UHFFFAOYSA-N 0.000 description 3
- AKPYCZBNKOMGTJ-UHFFFAOYSA-N C1CN(c2nonc2-[n+]2nc3nonc3[n-]2)CCO1 Chemical compound C1CN(c2nonc2-[n+]2nc3nonc3[n-]2)CCO1 AKPYCZBNKOMGTJ-UHFFFAOYSA-N 0.000 description 2
- KSFOVUSSGSKXFI-UJJXFSCMSA-N C=CC1=C(C)c2cc3[nH]c(cc4nc(cc5[nH]c(cc1n2)c(C)c5CCC(=O)O)C(CCC(=O)O)=C4C)c(C)c3C=C Chemical compound C=CC1=C(C)c2cc3[nH]c(cc4nc(cc5[nH]c(cc1n2)c(C)c5CCC(=O)O)C(CCC(=O)O)=C4C)c(C)c3C=C KSFOVUSSGSKXFI-UJJXFSCMSA-N 0.000 description 2
- LWBFJTHHMNOCQW-UHFFFAOYSA-N CC(=O)C1=C(C)NC(SCc2cccc([N+](=O)[O-])c2)=C(C#N)C1c1cccnc1 Chemical compound CC(=O)C1=C(C)NC(SCc2cccc([N+](=O)[O-])c2)=C(C#N)C1c1cccnc1 LWBFJTHHMNOCQW-UHFFFAOYSA-N 0.000 description 2
- WJTLHDXSWHHQMX-UHFFFAOYSA-N CC(=O)NC(CC(=O)c1ccc(Cl)cc1Cl)C(Cl)(Cl)Cl Chemical compound CC(=O)NC(CC(=O)c1ccc(Cl)cc1Cl)C(Cl)(Cl)Cl WJTLHDXSWHHQMX-UHFFFAOYSA-N 0.000 description 2
- XEBWQGVWTUSTLN-UHFFFAOYSA-M CC(=O)O[Hg]c1ccccc1 Chemical compound CC(=O)O[Hg]c1ccccc1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 2
- VFQVOTVAPPYKEC-UHFFFAOYSA-N CC(=O)Oc1cc(-c2coc3cc(OC(C)=O)c(OC(C)=O)c(OC(C)=O)c3c2=O)cc(OC(C)=O)c1OC(C)=O Chemical compound CC(=O)Oc1cc(-c2coc3cc(OC(C)=O)c(OC(C)=O)c(OC(C)=O)c3c2=O)cc(OC(C)=O)c1OC(C)=O VFQVOTVAPPYKEC-UHFFFAOYSA-N 0.000 description 2
- KPVSPKCWLWLEQI-UHFFFAOYSA-N CC(C)(C)C(=O)NCCCc1ccc([N+](=O)[O-])cc1 Chemical compound CC(C)(C)C(=O)NCCCc1ccc([N+](=O)[O-])cc1 KPVSPKCWLWLEQI-UHFFFAOYSA-N 0.000 description 2
- DARHOTOXJCIPCL-UHFFFAOYSA-N CC(C)N(CCC#N)S(=O)(=O)c1ccccc1[N+](=O)[O-] Chemical compound CC(C)N(CCC#N)S(=O)(=O)c1ccccc1[N+](=O)[O-] DARHOTOXJCIPCL-UHFFFAOYSA-N 0.000 description 2
- QRYRORQUOLYVBU-YBMSBYLISA-N CC(C)c1cc2c(c(O)c1O)[C@@]1(C(=O)O)CCCC(C)(C)C1CC2 Chemical compound CC(C)c1cc2c(c(O)c1O)[C@@]1(C(=O)O)CCCC(C)(C)C1CC2 QRYRORQUOLYVBU-YBMSBYLISA-N 0.000 description 2
- WCGDQFYUAYIZOI-TWGQIWQCSA-N CC/C(=C/c1ccc(O)c(OC)c1)[N+](=O)[O-] Chemical compound CC/C(=C/c1ccc(O)c(OC)c1)[N+](=O)[O-] WCGDQFYUAYIZOI-TWGQIWQCSA-N 0.000 description 2
- QQJVULBHWVKADA-UHFFFAOYSA-N CC1(C)CC(=O)C2=C(C1)OC(N)=C(C#N)C21CCCC1 Chemical compound CC1(C)CC(=O)C2=C(C1)OC(N)=C(C#N)C21CCCC1 QQJVULBHWVKADA-UHFFFAOYSA-N 0.000 description 2
- AWYMNGJAWMJBFS-UHFFFAOYSA-N CCC(=O)Cc1ccc(C(=O)Cc2ccc(Cl)cc2C(=O)O)cc1 Chemical compound CCC(=O)Cc1ccc(C(=O)Cc2ccc(Cl)cc2C(=O)O)cc1 AWYMNGJAWMJBFS-UHFFFAOYSA-N 0.000 description 2
- AYNJWHISZJGSHY-UHFFFAOYSA-N CCCCC(CC(=O)c1cccc(Br)c1)C(=O)O Chemical compound CCCCC(CC(=O)c1cccc(Br)c1)C(=O)O AYNJWHISZJGSHY-UHFFFAOYSA-N 0.000 description 2
- XBTWVJKPQPQTDW-UHFFFAOYSA-N CCN(CC)c1ccc(N)c(C)c1 Chemical compound CCN(CC)c1ccc(N)c(C)c1 XBTWVJKPQPQTDW-UHFFFAOYSA-N 0.000 description 2
- TZXJVHLCAYDZJW-UHFFFAOYSA-N CCOc1ccc(N/C(=N/N)c2ccc3ccccc3n2)cc1 Chemical compound CCOc1ccc(N/C(=N/N)c2ccc3ccccc3n2)cc1 TZXJVHLCAYDZJW-UHFFFAOYSA-N 0.000 description 2
- QGKYHNRIEASIQN-UHFFFAOYSA-N CCSc1sc(SC#N)cc1SC#N Chemical compound CCSc1sc(SC#N)cc1SC#N QGKYHNRIEASIQN-UHFFFAOYSA-N 0.000 description 2
- VIYLHAVXVNKQSD-UHFFFAOYSA-N CCc1c(C)sc(NC(=O)c2cccc([N+](=O)[O-])c2C)c1C(N)=O Chemical compound CCc1c(C)sc(NC(=O)c2cccc([N+](=O)[O-])c2C)c1C(N)=O VIYLHAVXVNKQSD-UHFFFAOYSA-N 0.000 description 2
- VALPCZQLSVAUBX-UHFFFAOYSA-N CCc1c(C)sc(NC(=O)c2ccoc2C)c1C(N)=O Chemical compound CCc1c(C)sc(NC(=O)c2ccoc2C)c1C(N)=O VALPCZQLSVAUBX-UHFFFAOYSA-N 0.000 description 2
- JIABWPFIQBTSFL-UHFFFAOYSA-N CCc1ccc(NC(Nc2ccc(CC)cc2)=C(S(=O)(=O)CC)S(=O)(=O)CC)cc1 Chemical compound CCc1ccc(NC(Nc2ccc(CC)cc2)=C(S(=O)(=O)CC)S(=O)(=O)CC)cc1 JIABWPFIQBTSFL-UHFFFAOYSA-N 0.000 description 2
- STXMSUGVXDMHKL-UHFFFAOYSA-N CCc1cccc(NC(=O)NC2CCCCC2)c1 Chemical compound CCc1cccc(NC(=O)NC2CCCCC2)c1 STXMSUGVXDMHKL-UHFFFAOYSA-N 0.000 description 2
- PYTNLSZCOMMFBA-UHFFFAOYSA-N CN(C)c1ccc(NC(=O)C2C3C=CC(C3)C2C(=O)O)cc1 Chemical compound CN(C)c1ccc(NC(=O)C2C3C=CC(C3)C2C(=O)O)cc1 PYTNLSZCOMMFBA-UHFFFAOYSA-N 0.000 description 2
- WVPOJZUKIIRHOQ-UHFFFAOYSA-N CN1CCc2c(sc(N)c2C#N)C1 Chemical compound CN1CCc2c(sc(N)c2C#N)C1 WVPOJZUKIIRHOQ-UHFFFAOYSA-N 0.000 description 2
- YDKAICSDAOTTCA-UHFFFAOYSA-N COC(=O)Oc1c(Cl)cc2oc(=O)sc2c1[N+](=O)[O-] Chemical compound COC(=O)Oc1c(Cl)cc2oc(=O)sc2c1[N+](=O)[O-] YDKAICSDAOTTCA-UHFFFAOYSA-N 0.000 description 2
- KOMBQMRNCMGUIA-UHFFFAOYSA-N COCCN1C(=O)C(O)=C(C(=O)c2ccc(OC)c(C)c2)C1c1ccncc1 Chemical compound COCCN1C(=O)C(O)=C(C(=O)c2ccc(OC)c(C)c2)C1c1ccncc1 KOMBQMRNCMGUIA-UHFFFAOYSA-N 0.000 description 2
- TYHVUEJVFMFXBK-UHFFFAOYSA-N COCc1cc(C(C)(C)C)c(O)c(O)c1C(C)(C)C Chemical compound COCc1cc(C(C)(C)C)c(O)c(O)c1C(C)(C)C TYHVUEJVFMFXBK-UHFFFAOYSA-N 0.000 description 2
- TUTKQLIXDCWWJG-VMPITWQZSA-N COc1cc(/C=C(\C)[N+](=O)[O-])cc(OC)c1OC Chemical compound COc1cc(/C=C(\C)[N+](=O)[O-])cc(OC)c1OC TUTKQLIXDCWWJG-VMPITWQZSA-N 0.000 description 2
- XZODRWNLPRGKLB-AWNIVKPZSA-N COc1cc(/C=C2\C(C)=C([N+](=O)[O-])CS2(=O)=O)ccc1O Chemical compound COc1cc(/C=C2\C(C)=C([N+](=O)[O-])CS2(=O)=O)ccc1O XZODRWNLPRGKLB-AWNIVKPZSA-N 0.000 description 2
- ONNCMRLFXKMFDF-UHFFFAOYSA-N COc1cc(NC(=O)COc2ccc(C)cc2C)ccc1CC(=O)c1ccco1 Chemical compound COc1cc(NC(=O)COc2ccc(C)cc2C)ccc1CC(=O)c1ccco1 ONNCMRLFXKMFDF-UHFFFAOYSA-N 0.000 description 2
- TWZMVQARIIRSDZ-UHFFFAOYSA-N COc1ccc(-c2ccc(CCC(=O)O)[nH]2)cc1 Chemical compound COc1ccc(-c2ccc(CCC(=O)O)[nH]2)cc1 TWZMVQARIIRSDZ-UHFFFAOYSA-N 0.000 description 2
- NIFANDXEDSJZOR-UHFFFAOYSA-N COc1ccc(-c2ccc(CCC(=O)O)n2-c2ccc(O)cc2)cc1 Chemical compound COc1ccc(-c2ccc(CCC(=O)O)n2-c2ccc(O)cc2)cc1 NIFANDXEDSJZOR-UHFFFAOYSA-N 0.000 description 2
- ZKWNOAWLDSIWEE-UHFFFAOYSA-N COc1ccc(-c2ccc(CCC(=O)O)o2)cc1 Chemical compound COc1ccc(-c2ccc(CCC(=O)O)o2)cc1 ZKWNOAWLDSIWEE-UHFFFAOYSA-N 0.000 description 2
- IEJVXWOVBNWQCY-UHFFFAOYSA-N COc1ccc(-c2nnc(N)o2)cc1 Chemical compound COc1ccc(-c2nnc(N)o2)cc1 IEJVXWOVBNWQCY-UHFFFAOYSA-N 0.000 description 2
- KDUUQROZVQGDTO-UHFFFAOYSA-N COc1ccc(NS(=O)(=O)c2cc(C(=O)Nc3ccc(C(=O)O)cc3)ccc2C)cc1 Chemical compound COc1ccc(NS(=O)(=O)c2cc(C(=O)Nc3ccc(C(=O)O)cc3)ccc2C)cc1 KDUUQROZVQGDTO-UHFFFAOYSA-N 0.000 description 2
- HSXGWEXIJUHZLK-UHFFFAOYSA-N COc1ccc(OC)c(N2C(=O)CC(Sc3nc4ccccc4s3)C2=O)c1 Chemical compound COc1ccc(OC)c(N2C(=O)CC(Sc3nc4ccccc4s3)C2=O)c1 HSXGWEXIJUHZLK-UHFFFAOYSA-N 0.000 description 2
- XFQADNIFKHSLBA-UHFFFAOYSA-N COc1ccc2[nH]cc(CCNC(=O)c3ccc([N+](=O)[O-])cc3)c2c1 Chemical compound COc1ccc2[nH]cc(CCNC(=O)c3ccc([N+](=O)[O-])cc3)c2c1 XFQADNIFKHSLBA-UHFFFAOYSA-N 0.000 description 2
- KJJGBFUOBDQHSH-UHFFFAOYSA-O C[n+]1sc(Nc2ccccc2)nc1-c1ccccc1.[Br-] Chemical compound C[n+]1sc(Nc2ccccc2)nc1-c1ccccc1.[Br-] KJJGBFUOBDQHSH-UHFFFAOYSA-O 0.000 description 2
- DUXOQCAGGZICSV-UHFFFAOYSA-N Cc1[nH]nc(-c2ccc(O)c(O)c2O)c1Oc1ccccc1 Chemical compound Cc1[nH]nc(-c2ccc(O)c(O)c2O)c1Oc1ccccc1 DUXOQCAGGZICSV-UHFFFAOYSA-N 0.000 description 2
- SNUFURQFLHHQQS-UHFFFAOYSA-N Cc1c2no[n+]([O-])c2c(C)[n+]([O-])[n+]1[O-] Chemical compound Cc1c2no[n+]([O-])c2c(C)[n+]([O-])[n+]1[O-] SNUFURQFLHHQQS-UHFFFAOYSA-N 0.000 description 2
- LHDATCZOUJTWRO-UHFFFAOYSA-N Cc1cc(=O)n2ccc(N)c(O)c2n1 Chemical compound Cc1cc(=O)n2ccc(N)c(O)c2n1 LHDATCZOUJTWRO-UHFFFAOYSA-N 0.000 description 2
- IOBDMYUXOGGIOJ-UHFFFAOYSA-N Cc1cc(C)n(-c2ccc3cccc([N+](=O)[O-])c3n2)n1 Chemical compound Cc1cc(C)n(-c2ccc3cccc([N+](=O)[O-])c3n2)n1 IOBDMYUXOGGIOJ-UHFFFAOYSA-N 0.000 description 2
- ZXKUBFNVCNOCSV-UHFFFAOYSA-N Cc1cc(O)ccc1NC(=O)c1ccccc1 Chemical compound Cc1cc(O)ccc1NC(=O)c1ccccc1 ZXKUBFNVCNOCSV-UHFFFAOYSA-N 0.000 description 2
- XIEFXNUAGJCARS-UHFFFAOYSA-N Cc1ccc(-c2ccc(CCC(=O)O)o2)cc1 Chemical compound Cc1ccc(-c2ccc(CCC(=O)O)o2)cc1 XIEFXNUAGJCARS-UHFFFAOYSA-N 0.000 description 2
- KHKAAHCGWUFMLI-UHFFFAOYSA-N Cc1ccc(-c2csc(N)c2C(N)=O)cc1C Chemical compound Cc1ccc(-c2csc(N)c2C(N)=O)cc1C KHKAAHCGWUFMLI-UHFFFAOYSA-N 0.000 description 2
- AGDSBIYIBMPBJF-UHFFFAOYSA-N Cc1ccc(OCCn2ccnc2)cc1 Chemical compound Cc1ccc(OCCn2ccnc2)cc1 AGDSBIYIBMPBJF-UHFFFAOYSA-N 0.000 description 2
- YOHYORAEXPNUJY-UHFFFAOYSA-N Cc1ccc(S(=O)(=O)Nc2cccc3ccc(-n4nc(C)cc4C)nc23)cc1 Chemical compound Cc1ccc(S(=O)(=O)Nc2cccc3ccc(-n4nc(C)cc4C)nc23)cc1 YOHYORAEXPNUJY-UHFFFAOYSA-N 0.000 description 2
- QGYAMNLNFAVLLE-UHFFFAOYSA-N Cc1ccccc1-c1nnc(N)s1 Chemical compound Cc1ccccc1-c1nnc(N)s1 QGYAMNLNFAVLLE-UHFFFAOYSA-N 0.000 description 2
- XLEFKEWFWKTLJH-UHFFFAOYSA-N Cc1nnc(SC2CC(=O)N(c3ccc(Br)cc3)C2=O)s1 Chemical compound Cc1nnc(SC2CC(=O)N(c3ccc(Br)cc3)C2=O)s1 XLEFKEWFWKTLJH-UHFFFAOYSA-N 0.000 description 2
- LGJAYNQTQBXABU-UHFFFAOYSA-N Cc1nnc(SC2CC(=O)N(c3ccc(Oc4ccccc4)cc3)C2=O)s1 Chemical compound Cc1nnc(SC2CC(=O)N(c3ccc(Oc4ccccc4)cc3)C2=O)s1 LGJAYNQTQBXABU-UHFFFAOYSA-N 0.000 description 2
- VDUYCGYCFGOFJD-UHFFFAOYSA-N Cc1sc(NC(=O)Cc2ccc([N+](=O)[O-])cc2)c(C(N)=O)c1C Chemical compound Cc1sc(NC(=O)Cc2ccc([N+](=O)[O-])cc2)c(C(N)=O)c1C VDUYCGYCFGOFJD-UHFFFAOYSA-N 0.000 description 2
- CLSUSRZJUQMOHH-UHFFFAOYSA-L Cl[Pt]Cl.N.N Chemical compound Cl[Pt]Cl.N.N CLSUSRZJUQMOHH-UHFFFAOYSA-L 0.000 description 2
- XJQUTHDJFOSTNZ-UHFFFAOYSA-N N#CSC(C#N)Cc1ccc([N+](=O)[O-])cc1 Chemical compound N#CSC(C#N)Cc1ccc([N+](=O)[O-])cc1 XJQUTHDJFOSTNZ-UHFFFAOYSA-N 0.000 description 2
- NOSBUFMQYHAZOZ-UHFFFAOYSA-N N#CSC(C#N)Cc1cccc(Cl)c1 Chemical compound N#CSC(C#N)Cc1cccc(Cl)c1 NOSBUFMQYHAZOZ-UHFFFAOYSA-N 0.000 description 2
- BZQNSPAPXZEASH-UHFFFAOYSA-N N#CSC(C#N)Cc1cccc([N+](=O)[O-])c1 Chemical compound N#CSC(C#N)Cc1cccc([N+](=O)[O-])c1 BZQNSPAPXZEASH-UHFFFAOYSA-N 0.000 description 2
- IEHPZQDZKHWGCT-UHFFFAOYSA-N N#CSC(C#N)Cc1ccccc1 Chemical compound N#CSC(C#N)Cc1ccccc1 IEHPZQDZKHWGCT-UHFFFAOYSA-N 0.000 description 2
- GKTKKZVFCLAHQX-UHFFFAOYSA-N N#CSc1cnc(NC2CCCCC2)s1 Chemical compound N#CSc1cnc(NC2CCCCC2)s1 GKTKKZVFCLAHQX-UHFFFAOYSA-N 0.000 description 2
- ZGXFRDITPRHFEY-UHFFFAOYSA-N N#Cc1ccc(Oc2ccc(C(=O)Nc3ccccc3)cc2)cc1 Chemical compound N#Cc1ccc(Oc2ccc(C(=O)Nc3ccccc3)cc2)cc1 ZGXFRDITPRHFEY-UHFFFAOYSA-N 0.000 description 2
- ZSWVADAIGMSQBB-UHFFFAOYSA-L N.N.O=C1O[Pt]OC(=O)C12CCC2 Chemical compound N.N.O=C1O[Pt]OC(=O)C12CCC2 ZSWVADAIGMSQBB-UHFFFAOYSA-L 0.000 description 2
- AOKUOQRFZXRQBM-UHFFFAOYSA-N NC(=O)c1c(-c2cccs2)csc1N Chemical compound NC(=O)c1c(-c2cccs2)csc1N AOKUOQRFZXRQBM-UHFFFAOYSA-N 0.000 description 2
- JJTZWRPLMGBWMZ-UHFFFAOYSA-N NC(=O)c1c(NC(=O)C2CCCO2)sc2c1CCCCCC2 Chemical compound NC(=O)c1c(NC(=O)C2CCCO2)sc2c1CCCCCC2 JJTZWRPLMGBWMZ-UHFFFAOYSA-N 0.000 description 2
- NLNRQJQXCQVDQJ-UHFFFAOYSA-N Nc1ccc(C(=O)c2ccc(N)c(N)c2)cc1N Chemical compound Nc1ccc(C(=O)c2ccc(N)c(N)c2)cc1N NLNRQJQXCQVDQJ-UHFFFAOYSA-N 0.000 description 2
- RCYNJDVUURMJOZ-UHFFFAOYSA-N Nc1ccc(Cc2ccc(N)c(O)c2)cc1O Chemical compound Nc1ccc(Cc2ccc(N)c(O)c2)cc1O RCYNJDVUURMJOZ-UHFFFAOYSA-N 0.000 description 2
- JKETWUADWJKEKN-UHFFFAOYSA-N Nc1ccc(S(=O)(=O)c2ccc(N)c(N)c2)cc1N Chemical compound Nc1ccc(S(=O)(=O)c2ccc(N)c(N)c2)cc1N JKETWUADWJKEKN-UHFFFAOYSA-N 0.000 description 2
- NIOOKXAMJQVDGB-UHFFFAOYSA-N Nc1ccccc1S(=O)(=O)Nc1cccc2cccnc12 Chemical compound Nc1ccccc1S(=O)(=O)Nc1cccc2cccnc12 NIOOKXAMJQVDGB-UHFFFAOYSA-N 0.000 description 2
- BEZQTLICSGQQAI-MDZDMXLPSA-N O=C(/C=C/c1ccco1)c1ccc(NC(=O)c2ccco2)cc1 Chemical compound O=C(/C=C/c1ccco1)c1ccc(NC(=O)c2ccco2)cc1 BEZQTLICSGQQAI-MDZDMXLPSA-N 0.000 description 2
- DIWKTRPJGHVDAL-UHFFFAOYSA-N O=C(CN1CCCCC1)Nc1ccc(S(=O)(=O)N2CCOCC2)cc1 Chemical compound O=C(CN1CCCCC1)Nc1ccc(S(=O)(=O)N2CCOCC2)cc1 DIWKTRPJGHVDAL-UHFFFAOYSA-N 0.000 description 2
- BXXKRNGBUASLPZ-UHFFFAOYSA-N O=C(Cc1ccc([N+](=O)[O-])cc1)c1ccc(Br)o1 Chemical compound O=C(Cc1ccc([N+](=O)[O-])cc1)c1ccc(Br)o1 BXXKRNGBUASLPZ-UHFFFAOYSA-N 0.000 description 2
- HUWQLXPGQPSYNT-UHFFFAOYSA-N O=C(Cc1ccc2c(c1)OCCO2)c1cc2ccccc2o1 Chemical compound O=C(Cc1ccc2c(c1)OCCO2)c1cc2ccccc2o1 HUWQLXPGQPSYNT-UHFFFAOYSA-N 0.000 description 2
- XCLXFOOWQUUCPI-UHFFFAOYSA-N O=C(Cc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1)N1CCOCC1 Chemical compound O=C(Cc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1)N1CCOCC1 XCLXFOOWQUUCPI-UHFFFAOYSA-N 0.000 description 2
- YYKGZYGSFFMVEP-UHFFFAOYSA-N O=C(Cc1ccccc1)c1ccc(O)c(O)c1O Chemical compound O=C(Cc1ccccc1)c1ccc(O)c(O)c1O YYKGZYGSFFMVEP-UHFFFAOYSA-N 0.000 description 2
- JNFWHHDYBSBYJJ-UHFFFAOYSA-N O=C(Nc1nc2c(s1)CCCC2)c1cccs1 Chemical compound O=C(Nc1nc2c(s1)CCCC2)c1cccs1 JNFWHHDYBSBYJJ-UHFFFAOYSA-N 0.000 description 2
- CDBQETHZTGGQQM-SNAWJCMRSA-N O=C(O)COc1cccc(/C=C/[N+](=O)[O-])c1 Chemical compound O=C(O)COc1cccc(/C=C/[N+](=O)[O-])c1 CDBQETHZTGGQQM-SNAWJCMRSA-N 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N O=C(O)c1cc(O)c(O)c(O)c1 Chemical compound O=C(O)c1cc(O)c(O)c(O)c1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- KMJPKUVSXFVQGZ-WQLSNUALSA-N O=C(O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(=O)c2c(O)c(O)cc([C@H]3Oc4cc(O)cc(O)c4C[C@H]3O)c2c1)c1cc(O)c(O)c(O)c1 Chemical compound O=C(O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(=O)c2c(O)c(O)cc([C@H]3Oc4cc(O)cc(O)c4C[C@H]3O)c2c1)c1cc(O)c(O)c(O)c1 KMJPKUVSXFVQGZ-WQLSNUALSA-N 0.000 description 2
- ZEASWHWETFMWCV-ISBUVJFSSA-N O=C(O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(=O)c2c(O)c(O)cc([C@H]3Oc4cc(O)cc(O)c4C[C@H]3OC(=O)c3cc(O)c(O)c(O)c3)c2c1)c1cc(O)c(O)c(O)c1 Chemical compound O=C(O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(=O)c2c(O)c(O)cc([C@H]3Oc4cc(O)cc(O)c4C[C@H]3OC(=O)c3cc(O)c(O)c(O)c3)c2c1)c1cc(O)c(O)c(O)c1 ZEASWHWETFMWCV-ISBUVJFSSA-N 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N O=C(O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(O)c(O)c1)c1cc(O)c(O)c(O)c1 Chemical compound O=C(O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(O)c(O)c1)c1cc(O)c(O)c(O)c1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- CTVAVEOYQKVFFY-DUSGSIEYSA-N O=C(O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(O)c(O)c1-c1c([C@H]2Oc3cc(O)cc(O)c3C[C@H]2O)cc(O)c(O)c1O)c1cc(O)c(O)c(O)c1 Chemical compound O=C(O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(O)c(O)c1-c1c([C@H]2Oc3cc(O)cc(O)c3C[C@H]2O)cc(O)c(O)c1O)c1cc(O)c(O)c(O)c1 CTVAVEOYQKVFFY-DUSGSIEYSA-N 0.000 description 2
- YUULFXAQUWEYNP-GXAWFILRSA-N O=C(O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(O)c(O)c1-c1c([C@H]2Oc3cc(O)cc(O)c3C[C@H]2OC(=O)c2cc(O)c(O)c(O)c2)cc(O)c(O)c1O)c1cc(O)c(O)c(O)c1 Chemical compound O=C(O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(O)c(O)c1-c1c([C@H]2Oc3cc(O)cc(O)c3C[C@H]2OC(=O)c2cc(O)c(O)c(O)c2)cc(O)c(O)c1O)c1cc(O)c(O)c(O)c1 YUULFXAQUWEYNP-GXAWFILRSA-N 0.000 description 2
- UGNWTBMOAKPKBL-UHFFFAOYSA-N O=C1C(Cl)=C(Cl)C(=O)C(Cl)=C1Cl Chemical compound O=C1C(Cl)=C(Cl)C(=O)C(Cl)=C1Cl UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 2
- PKSMVUKHFWNIGK-UHFFFAOYSA-N O=C1CC(Sc2ccccn2)C(=O)N1c1cccc(Cl)c1Cl Chemical compound O=C1CC(Sc2ccccn2)C(=O)N1c1cccc(Cl)c1Cl PKSMVUKHFWNIGK-UHFFFAOYSA-N 0.000 description 2
- VBDHCTISBWBOBC-UHFFFAOYSA-N O=C1CC(Sc2nc3ccccc3s2)C(=O)N1c1ccccc1I Chemical compound O=C1CC(Sc2nc3ccccc3s2)C(=O)N1c1ccccc1I VBDHCTISBWBOBC-UHFFFAOYSA-N 0.000 description 2
- FEYSEBSALRMGIN-UHFFFAOYSA-N O=C1CC(Sc2nnnn2-c2ccccc2)C(=O)N1c1ccc([N+](=O)[O-])cc1 Chemical compound O=C1CC(Sc2nnnn2-c2ccccc2)C(=O)N1c1ccc([N+](=O)[O-])cc1 FEYSEBSALRMGIN-UHFFFAOYSA-N 0.000 description 2
- VSJCDPYIMBSOKN-LSDHHAIUSA-N O=C1c2ccc(O)cc2O[C@H](c2cc(O)c(O)c(O)c2)[C@H]1O Chemical compound O=C1c2ccc(O)cc2O[C@H](c2cc(O)c(O)c(O)c2)[C@H]1O VSJCDPYIMBSOKN-LSDHHAIUSA-N 0.000 description 2
- LSXKCFHWDFNYMH-UHFFFAOYSA-N O=[N+]([O-])c1ccc(SCc2ccco2)c2cccnc12 Chemical compound O=[N+]([O-])c1ccc(SCc2ccco2)c2cccnc12 LSXKCFHWDFNYMH-UHFFFAOYSA-N 0.000 description 2
- VAOCIPZCVAFPGT-UHFFFAOYSA-N O=[N+]([O-])c1ccc2[nH]c(-c3ccco3)nc2c1 Chemical compound O=[N+]([O-])c1ccc2[nH]c(-c3ccco3)nc2c1 VAOCIPZCVAFPGT-UHFFFAOYSA-N 0.000 description 2
- DFURNQJNFBMYHM-UHFFFAOYSA-N O=c1c(-c2cc(O)c(O)c(O)c2)coc2cc(O)c(O)c(O)c12 Chemical compound O=c1c(-c2cc(O)c(O)c(O)c2)coc2cc(O)c(O)c(O)c12 DFURNQJNFBMYHM-UHFFFAOYSA-N 0.000 description 2
- IKMDFBPHZNJCSN-UHFFFAOYSA-N O=c1c(O)c(-c2cc(O)c(O)c(O)c2)oc2cc(O)cc(O)c12 Chemical compound O=c1c(O)c(-c2cc(O)c(O)c(O)c2)oc2cc(O)cc(O)c12 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 2
- IPMYMEWFZKHGAX-ZKSIBHASSA-N O=c1c(O)cc([C@H]2Oc3cc(O)cc(O)c3C[C@H]2O)cc2c([C@H]3Oc4cc(O)cc(O)c4C[C@H]3O)cc(O)c(O)c12 Chemical compound O=c1c(O)cc([C@H]2Oc3cc(O)cc(O)c3C[C@H]2O)cc2c([C@H]3Oc4cc(O)cc(O)c4C[C@H]3O)cc(O)c(O)c12 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 description 2
- SPQGLWVRJNKSPU-FOIQADDNSA-N O=c1c(O)cccc2c([C@H]3Oc4cc(O)cc(O)c4C[C@H]3O)cc(O)c(O)c12 Chemical compound O=c1c(O)cccc2c([C@H]3Oc4cc(O)cc(O)c4C[C@H]3O)cc(O)c(O)c12 SPQGLWVRJNKSPU-FOIQADDNSA-N 0.000 description 2
- OLSYHLURTGEIBH-UHFFFAOYSA-N O=c1c(O)cccc2ccc(O)c(O)c12 Chemical compound O=c1c(O)cccc2ccc(O)c(O)c12 OLSYHLURTGEIBH-UHFFFAOYSA-N 0.000 description 2
- IMCHHEFYSSYRFL-UHFFFAOYSA-N O=c1oc2cc(Br)c(O)c(Br)c2s1 Chemical compound O=c1oc2cc(Br)c(O)c(Br)c2s1 IMCHHEFYSSYRFL-UHFFFAOYSA-N 0.000 description 2
- MWKGMZRDURKJEZ-UHFFFAOYSA-O [Br-].c1ccc(Nc2nc(-c3ccccc3)[n+](-c3ccccc3)s2)cc1 Chemical compound [Br-].c1ccc(Nc2nc(-c3ccccc3)[n+](-c3ccccc3)s2)cc1 MWKGMZRDURKJEZ-UHFFFAOYSA-O 0.000 description 2
- JQPAQHRUZOUMMG-UHFFFAOYSA-O [Cl-].c1ccc(CNc2nc(-c3ccccc3)[n+](-c3ccccc3)s2)cc1 Chemical compound [Cl-].c1ccc(CNc2nc(-c3ccccc3)[n+](-c3ccccc3)s2)cc1 JQPAQHRUZOUMMG-UHFFFAOYSA-O 0.000 description 2
- RKUDRJTZBDEGNP-YIXXDRMTSA-N [H][C@@]1(OC(=O)c2cc(O)c(O)c(O)c2)Cc2c(OC(=O)c3cc(O)c(O)c(O)c3)cc(O)cc2O[C@@H]1c1cc(O)c(O)c(O)c1 Chemical compound [H][C@@]1(OC(=O)c2cc(O)c(O)c(O)c2)Cc2c(OC(=O)c3cc(O)c(O)c(O)c3)cc(O)cc2O[C@@H]1c1cc(O)c(O)c(O)c1 RKUDRJTZBDEGNP-YIXXDRMTSA-N 0.000 description 2
- MDASWRVQPNUUNC-UHFFFAOYSA-N Brc1ccc(-c2nc3ccccc3[nH]2)o1 Chemical compound Brc1ccc(-c2nc3ccccc3[nH]2)o1 MDASWRVQPNUUNC-UHFFFAOYSA-N 0.000 description 1
- KGCJOZYAQSYFNC-NXSPSANLSA-N Brc1ccc(-c2nc3ccccc3[nH]2)o1.CC(C)(C)c1c(C(=O)O)nnn1-c1nonc1N.CC(C)(O)c1cnnn1-c1nonc1N.CC(C)c1c(C(=O)O)nnn1-c1nonc1N.CC(O)c1cnnn1-c1nonc1N.COC(=O)c1nnn(-c2nonc2N)c1C(C)C.Cc1c([C@H](C)O)nnn1-c1nonc1N.Cc1ccc(-c2c(C(=O)O)nnn2-c2nonc2N)cc1.Nc1nonc1-n1nnc(CO)c1CO.O=C(O)CCc1ccc(-c2cccs2)o1.O=[N+]([O-])c1ccc2[nH]c(-c3ccco3)nc2c1 Chemical compound Brc1ccc(-c2nc3ccccc3[nH]2)o1.CC(C)(C)c1c(C(=O)O)nnn1-c1nonc1N.CC(C)(O)c1cnnn1-c1nonc1N.CC(C)c1c(C(=O)O)nnn1-c1nonc1N.CC(O)c1cnnn1-c1nonc1N.COC(=O)c1nnn(-c2nonc2N)c1C(C)C.Cc1c([C@H](C)O)nnn1-c1nonc1N.Cc1ccc(-c2c(C(=O)O)nnn2-c2nonc2N)cc1.Nc1nonc1-n1nnc(CO)c1CO.O=C(O)CCc1ccc(-c2cccs2)o1.O=[N+]([O-])c1ccc2[nH]c(-c3ccco3)nc2c1 KGCJOZYAQSYFNC-NXSPSANLSA-N 0.000 description 1
- ZLCKKIREMLSIIX-UHFFFAOYSA-N Brc1ccc(C2Nc3ccccc3N2)o1 Chemical compound Brc1ccc(C2Nc3ccccc3N2)o1 ZLCKKIREMLSIIX-UHFFFAOYSA-N 0.000 description 1
- YOXFAOPGXOYQDY-UHFFFAOYSA-N C=CCOC(=O)c1nnn(-c2nonc2N)c1C Chemical compound C=CCOC(=O)c1nnn(-c2nonc2N)c1C YOXFAOPGXOYQDY-UHFFFAOYSA-N 0.000 description 1
- JXFUHPCPFUHHCH-YBPFIXRVSA-N C=CCOC(=O)c1nnn(-c2nonc2N)c1C.CCOC(=O)c1nnn(-c2nonc2N)c1C12CC3CC(CC(C3)C1)C2.CC[C@](C)(O)c1c([C@](C)(O)CC)nnn1-c1nonc1N.CN(C)Cc1c(C(=O)O)nnn1-c1nonc1N.COCCOC(=O)c1nnn(-c2nonc2N)c1C.COCc1c(C(=O)O)nnn1-c1nonc1N.COCc1c(C(=O)OC)nnn1-c1nonc1N.Cc1c(C(=O)OC(C)(C)C)nnn1-c1nonc1N.Cc1ccccc1-c1nnc(N)s1.Cl.Nc1ncc(-c2c(O)c(Cl)c(Cl)c(O)c2Cl)s1 Chemical compound C=CCOC(=O)c1nnn(-c2nonc2N)c1C.CCOC(=O)c1nnn(-c2nonc2N)c1C12CC3CC(CC(C3)C1)C2.CC[C@](C)(O)c1c([C@](C)(O)CC)nnn1-c1nonc1N.CN(C)Cc1c(C(=O)O)nnn1-c1nonc1N.COCCOC(=O)c1nnn(-c2nonc2N)c1C.COCc1c(C(=O)O)nnn1-c1nonc1N.COCc1c(C(=O)OC)nnn1-c1nonc1N.Cc1c(C(=O)OC(C)(C)C)nnn1-c1nonc1N.Cc1ccccc1-c1nnc(N)s1.Cl.Nc1ncc(-c2c(O)c(Cl)c(Cl)c(O)c2Cl)s1 JXFUHPCPFUHHCH-YBPFIXRVSA-N 0.000 description 1
- HLBCHSFTPOTSLF-UHFFFAOYSA-N CC(C)(C)c1c(C(=O)O)nnn1-c1nonc1N Chemical compound CC(C)(C)c1c(C(=O)O)nnn1-c1nonc1N HLBCHSFTPOTSLF-UHFFFAOYSA-N 0.000 description 1
- CXZZGGPNAGYJHU-UHFFFAOYSA-N CC(C)(O)c1cn(-c2nonc2N)nn1 Chemical compound CC(C)(O)c1cn(-c2nonc2N)nn1 CXZZGGPNAGYJHU-UHFFFAOYSA-N 0.000 description 1
- UAQQJLKNACTKTL-UHFFFAOYSA-N CC(C)(O)c1cnnn1-c1nonc1N Chemical compound CC(C)(O)c1cnnn1-c1nonc1N UAQQJLKNACTKTL-UHFFFAOYSA-N 0.000 description 1
- QDMPWBKKMIUHSM-UHFFFAOYSA-N CC(C)(O)c1nnn(-c2nonc2N)c1C(C)(C)O Chemical compound CC(C)(O)c1nnn(-c2nonc2N)c1C(C)(C)O QDMPWBKKMIUHSM-UHFFFAOYSA-N 0.000 description 1
- WPEYHXAUVAYIRI-UHFFFAOYSA-N CC(C)c1c(C(=O)O)nnn1-c1nonc1N Chemical compound CC(C)c1c(C(=O)O)nnn1-c1nonc1N WPEYHXAUVAYIRI-UHFFFAOYSA-N 0.000 description 1
- HMFQNCDFAMDXHZ-UHFFFAOYSA-N CC(O)c1cn(-c2nonc2N)nn1 Chemical compound CC(O)c1cn(-c2nonc2N)nn1 HMFQNCDFAMDXHZ-UHFFFAOYSA-N 0.000 description 1
- VZZSDBARLBLZDU-UHFFFAOYSA-N CC(O)c1cnnn1-c1nonc1N Chemical compound CC(O)c1cnnn1-c1nonc1N VZZSDBARLBLZDU-UHFFFAOYSA-N 0.000 description 1
- NTRFOROTAPAYSK-UHFFFAOYSA-N CCCc1c(C(=O)O)nnn1-c1nonc1N Chemical compound CCCc1c(C(=O)O)nnn1-c1nonc1N NTRFOROTAPAYSK-UHFFFAOYSA-N 0.000 description 1
- LGXVYKHRKQTUCY-UHFFFAOYSA-N CCOC(=O)c1nnn(-c2nonc2N)c1C12CC3CC(CC(C3)C1)C2 Chemical compound CCOC(=O)c1nnn(-c2nonc2N)c1C12CC3CC(CC(C3)C1)C2 LGXVYKHRKQTUCY-UHFFFAOYSA-N 0.000 description 1
- DJARTFOWJAPNSO-UHFFFAOYSA-N CCOC(=O)c1nnn(-c2nonc2N)c1CC Chemical compound CCOC(=O)c1nnn(-c2nonc2N)c1CC DJARTFOWJAPNSO-UHFFFAOYSA-N 0.000 description 1
- PYZJFRNVKPZAAR-NEPJUHHUSA-N CC[C@](C)(O)c1c([C@](C)(O)CC)nnn1-c1nonc1N Chemical compound CC[C@](C)(O)c1c([C@](C)(O)CC)nnn1-c1nonc1N PYZJFRNVKPZAAR-NEPJUHHUSA-N 0.000 description 1
- ZKHXMTFNDBEBNH-UHFFFAOYSA-N CCc1c(C(=O)OC)nnn1-c1nonc1N Chemical compound CCc1c(C(=O)OC)nnn1-c1nonc1N ZKHXMTFNDBEBNH-UHFFFAOYSA-N 0.000 description 1
- YRJXWPXBXAICEY-AATRIKPKSA-N CCc1ccc(/C=C/C(=O)O)s1 Chemical compound CCc1ccc(/C=C/C(=O)O)s1 YRJXWPXBXAICEY-AATRIKPKSA-N 0.000 description 1
- CFCCXXJIZVLXEO-FQDVUMEHSA-N CCc1ccc(/C=C/C(=O)O)s1.COc1ccc(-c2ccc(CCC(=O)O)[nH]2)cc1.COc1ccc(-c2ccc(CCC(=O)O)o2)cc1.Cc1ccc(-c2ccc(CCC(=O)O)o2)cc1.O=C(O)/C=C/c1ccc(-c2ccc(F)cc2)o1.O=C(O)/C=C/c1ccc(-c2ccccc2)o1.O=C(O)CCc1ccc(-c2ccc(F)cc2)o1.O=C(O)CCc1ccc(-c2ccccc2)o1.O=C(O)CCc1ncc(-c2ccc(Cl)cc2)o1.O=C(O)CCc1ncc(-c2ccccc2)o1 Chemical compound CCc1ccc(/C=C/C(=O)O)s1.COc1ccc(-c2ccc(CCC(=O)O)[nH]2)cc1.COc1ccc(-c2ccc(CCC(=O)O)o2)cc1.Cc1ccc(-c2ccc(CCC(=O)O)o2)cc1.O=C(O)/C=C/c1ccc(-c2ccc(F)cc2)o1.O=C(O)/C=C/c1ccc(-c2ccccc2)o1.O=C(O)CCc1ccc(-c2ccc(F)cc2)o1.O=C(O)CCc1ccc(-c2ccccc2)o1.O=C(O)CCc1ncc(-c2ccc(Cl)cc2)o1.O=C(O)CCc1ncc(-c2ccccc2)o1 CFCCXXJIZVLXEO-FQDVUMEHSA-N 0.000 description 1
- CKPVJVQCAPTESJ-UHFFFAOYSA-N CCc1cnnn1-c1nonc1N Chemical compound CCc1cnnn1-c1nonc1N CKPVJVQCAPTESJ-UHFFFAOYSA-N 0.000 description 1
- ZWFIUXTWQRVAQO-UHFFFAOYSA-N CN(C)Cc1c(C(=O)O)nnn1-c1nonc1N Chemical compound CN(C)Cc1c(C(=O)O)nnn1-c1nonc1N ZWFIUXTWQRVAQO-UHFFFAOYSA-N 0.000 description 1
- DVYVBENBIMEAJZ-UHFFFAOYSA-N CN(CC(=O)O)c1ccccc1.[H]Cl Chemical compound CN(CC(=O)O)c1ccccc1.[H]Cl DVYVBENBIMEAJZ-UHFFFAOYSA-N 0.000 description 1
- COMLGXMMDMCVKE-FNORWQNLSA-N COC(=O)/C=C/c1ccc(-c2cccs2)o1 Chemical compound COC(=O)/C=C/c1ccc(-c2cccs2)o1 COMLGXMMDMCVKE-FNORWQNLSA-N 0.000 description 1
- SLGUCNFTLVXCOQ-UHFFFAOYSA-N COC(=O)CCc1ccc(-c2cccs2)o1 Chemical compound COC(=O)CCc1ccc(-c2cccs2)o1 SLGUCNFTLVXCOQ-UHFFFAOYSA-N 0.000 description 1
- QRHXGSWMZNLUNV-UHFFFAOYSA-N COC(=O)c1nnn(-c2nonc2N)c1C(C)(C)C Chemical compound COC(=O)c1nnn(-c2nonc2N)c1C(C)(C)C QRHXGSWMZNLUNV-UHFFFAOYSA-N 0.000 description 1
- LOXASWJRZJBZKW-UHFFFAOYSA-N COC(=O)c1nnn(-c2nonc2N)c1C(C)C Chemical compound COC(=O)c1nnn(-c2nonc2N)c1C(C)C LOXASWJRZJBZKW-UHFFFAOYSA-N 0.000 description 1
- UOWYVTUFHZGHPQ-UHFFFAOYSA-N COCCOC(=O)c1nnn(-c2nonc2N)c1C Chemical compound COCCOC(=O)c1nnn(-c2nonc2N)c1C UOWYVTUFHZGHPQ-UHFFFAOYSA-N 0.000 description 1
- MFCNFXUMJZQACX-UHFFFAOYSA-N COCc1c(C(=O)O)nnn1-c1nonc1N Chemical compound COCc1c(C(=O)O)nnn1-c1nonc1N MFCNFXUMJZQACX-UHFFFAOYSA-N 0.000 description 1
- VYOYTIDHHQHZSM-UHFFFAOYSA-N COCc1c(C(=O)OC)nnn1-c1nonc1N Chemical compound COCc1c(C(=O)OC)nnn1-c1nonc1N VYOYTIDHHQHZSM-UHFFFAOYSA-N 0.000 description 1
- AVZCXKHOSCMMNU-UHFFFAOYSA-N COc1cc(-c2ccc(NC(=O)c3ccoc3C)c(OC)c2)ccc1CC(=O)c1ccoc1C Chemical compound COc1cc(-c2ccc(NC(=O)c3ccoc3C)c(OC)c2)ccc1CC(=O)c1ccoc1C AVZCXKHOSCMMNU-UHFFFAOYSA-N 0.000 description 1
- GJNYWUUUDBPQNF-UHFFFAOYSA-N COc1cc(-c2ccc(NC(=O)c3ccoc3C)c(OC)c2)ccc1NC(=O)c1ccoc1C Chemical compound COc1cc(-c2ccc(NC(=O)c3ccoc3C)c(OC)c2)ccc1NC(=O)c1ccoc1C GJNYWUUUDBPQNF-UHFFFAOYSA-N 0.000 description 1
- CBLNIPSJUSYDIX-UHFFFAOYSA-O C[n+]1c(SCC(=O)O)sc2ccccc21.[Br-] Chemical compound C[n+]1c(SCC(=O)O)sc2ccccc21.[Br-] CBLNIPSJUSYDIX-UHFFFAOYSA-O 0.000 description 1
- XFFORLCXIDRVHA-YIPNIGHSSA-O C[n+]1sc(Nc2ccccc2)nc1-c1ccccc1.O=C(O)/C=C/c1ccc(-c2ccccc2Cl)o1.O=C(O)CCC1=CC=C(c2cccs2)C1.O=C(O)CCN1CCC(c2ccccc2)=N1.O=C(O)CCc1nc(-c2ccccc2)no1.O=C(O)CCc1ncc(-c2ccc(Br)cc2)o1.O=C(O)CCc1nnc(-c2ccccc2)o1.O=C(O)CCn1nc(-c2ccccc2)ccc1=O.O=C(O)CSc1nc(-c2ccccc2)cs1.O=[N+]([O-])/C=C/c1ccc(-c2ccccc2)o1.[Br-] Chemical compound C[n+]1sc(Nc2ccccc2)nc1-c1ccccc1.O=C(O)/C=C/c1ccc(-c2ccccc2Cl)o1.O=C(O)CCC1=CC=C(c2cccs2)C1.O=C(O)CCN1CCC(c2ccccc2)=N1.O=C(O)CCc1nc(-c2ccccc2)no1.O=C(O)CCc1ncc(-c2ccc(Br)cc2)o1.O=C(O)CCc1nnc(-c2ccccc2)o1.O=C(O)CCn1nc(-c2ccccc2)ccc1=O.O=C(O)CSc1nc(-c2ccccc2)cs1.O=[N+]([O-])/C=C/c1ccc(-c2ccccc2)o1.[Br-] XFFORLCXIDRVHA-YIPNIGHSSA-O 0.000 description 1
- GLKVKXXLWPVOFX-UHFFFAOYSA-N Cc1c(C(=O)OC(C)(C)C)nnn1-c1nonc1N Chemical compound Cc1c(C(=O)OC(C)(C)C)nnn1-c1nonc1N GLKVKXXLWPVOFX-UHFFFAOYSA-N 0.000 description 1
- KUDMMCRYZIYTOB-UHFFFAOYSA-N Cc1c(C(=O)OC(C)C)nnn1-c1nonc1N Chemical compound Cc1c(C(=O)OC(C)C)nnn1-c1nonc1N KUDMMCRYZIYTOB-UHFFFAOYSA-N 0.000 description 1
- BYCCPVSOEDMPLO-UHFFFAOYSA-N Cc1c(C(C)O)nnn1-c1nonc1N Chemical compound Cc1c(C(C)O)nnn1-c1nonc1N BYCCPVSOEDMPLO-UHFFFAOYSA-N 0.000 description 1
- BYCCPVSOEDMPLO-BYPYZUCNSA-N Cc1c([C@H](C)O)nnn1-c1nonc1N Chemical compound Cc1c([C@H](C)O)nnn1-c1nonc1N BYCCPVSOEDMPLO-BYPYZUCNSA-N 0.000 description 1
- RQGGLALGFGLWAL-UHFFFAOYSA-N Cc1ccc(-c2c(C(=O)O)nnn2-c2nonc2N)cc1 Chemical compound Cc1ccc(-c2c(C(=O)O)nnn2-c2nonc2N)cc1 RQGGLALGFGLWAL-UHFFFAOYSA-N 0.000 description 1
- DREIEBOUXLZJCA-UHFFFAOYSA-N Cc1ccc(-c2ccc(=O)n(CCC(=O)O)n2)cc1 Chemical compound Cc1ccc(-c2ccc(=O)n(CCC(=O)O)n2)cc1 DREIEBOUXLZJCA-UHFFFAOYSA-N 0.000 description 1
- ZEHGJLZZGNVEEB-WWFSYHMNSA-M Cc1ccc(-c2ccc(=O)n(CCC(=O)O)n2)cc1.Cc1ccc(-c2csc(N)c2C(N)=O)cc1C.O=C(O)/C=C/c1ccc(-c2ccccc2Br)o1.O=C(O)CCc1nc(-c2ccccc2F)no1.O=C(O)CCn1nc(-c2ccc(Cl)cc2)ccc1=O.O=C(O)CCn1nc(-c2ccc(F)cc2)ccc1=O.O=C(O)COC1C=C(n2cnnn2)C=CC1.O=C(O)CSc1nnc(-c2ccccc2)o1.O=C([O-])CSc1ccc2ccccc2n1 Chemical compound Cc1ccc(-c2ccc(=O)n(CCC(=O)O)n2)cc1.Cc1ccc(-c2csc(N)c2C(N)=O)cc1C.O=C(O)/C=C/c1ccc(-c2ccccc2Br)o1.O=C(O)CCc1nc(-c2ccccc2F)no1.O=C(O)CCn1nc(-c2ccc(Cl)cc2)ccc1=O.O=C(O)CCn1nc(-c2ccc(F)cc2)ccc1=O.O=C(O)COC1C=C(n2cnnn2)C=CC1.O=C(O)CSc1nnc(-c2ccccc2)o1.O=C([O-])CSc1ccc2ccccc2n1 ZEHGJLZZGNVEEB-WWFSYHMNSA-M 0.000 description 1
- JSMYBMVEUSDVSN-UHFFFAOYSA-N Cc1ccc(-c2ccc(C(=O)O)s2)o1 Chemical compound Cc1ccc(-c2ccc(C(=O)O)s2)o1 JSMYBMVEUSDVSN-UHFFFAOYSA-N 0.000 description 1
- BKGFCODNMAMEBO-UHFFFAOYSA-N Cl.Nc1ncc(-c2c(O)c(Cl)c(Cl)c(O)c2Cl)s1 Chemical compound Cl.Nc1ncc(-c2c(O)c(Cl)c(Cl)c(O)c2Cl)s1 BKGFCODNMAMEBO-UHFFFAOYSA-N 0.000 description 1
- CIYUYOJEJKEXRF-UHFFFAOYSA-N Cl.Nc1ncc(C2=C(Cl)C(O)C(Cl)=C(Cl)C2O)s1 Chemical compound Cl.Nc1ncc(C2=C(Cl)C(O)C(Cl)=C(Cl)C2O)s1 CIYUYOJEJKEXRF-UHFFFAOYSA-N 0.000 description 1
- OHKLNNMLTJFVDC-UHFFFAOYSA-N Nc1nonc1-n1cc(CO)nn1 Chemical compound Nc1nonc1-n1cc(CO)nn1 OHKLNNMLTJFVDC-UHFFFAOYSA-N 0.000 description 1
- KHLKPBNYKKVIAM-UHFFFAOYSA-N Nc1nonc1-n1nnc(C(=O)O)c1-c1ccccc1 Chemical compound Nc1nonc1-n1nnc(C(=O)O)c1-c1ccccc1 KHLKPBNYKKVIAM-UHFFFAOYSA-N 0.000 description 1
- MKMLUDAHTGRCOS-UHFFFAOYSA-N Nc1nonc1-n1nnc(CO)c1CO Chemical compound Nc1nonc1-n1nnc(CO)c1CO MKMLUDAHTGRCOS-UHFFFAOYSA-N 0.000 description 1
- UZQQZYKUNOOWQU-UHFFFAOYSA-N Nc1nonc1-n1nncc1CO Chemical compound Nc1nonc1-n1nncc1CO UZQQZYKUNOOWQU-UHFFFAOYSA-N 0.000 description 1
- VBHJKWPYXPCTHK-UHFFFAOYSA-N O=C(CCc1ccco1)OCc1cccs1 Chemical compound O=C(CCc1ccco1)OCc1cccs1 VBHJKWPYXPCTHK-UHFFFAOYSA-N 0.000 description 1
- LHPYNYVABBATBM-SOFGYWHQSA-N O=C(O)/C=C/c1ccc(-c2ccc(F)cc2)o1 Chemical compound O=C(O)/C=C/c1ccc(-c2ccc(F)cc2)o1 LHPYNYVABBATBM-SOFGYWHQSA-N 0.000 description 1
- GGEKLCJBCQCQPL-VQHVLOKHSA-N O=C(O)/C=C/c1ccc(-c2ccccc2)o1 Chemical compound O=C(O)/C=C/c1ccc(-c2ccccc2)o1 GGEKLCJBCQCQPL-VQHVLOKHSA-N 0.000 description 1
- FVCBRTBMTOOITC-SOFGYWHQSA-N O=C(O)/C=C/c1ccc(-c2ccccc2Br)o1 Chemical compound O=C(O)/C=C/c1ccc(-c2ccccc2Br)o1 FVCBRTBMTOOITC-SOFGYWHQSA-N 0.000 description 1
- IZITWMKBFNBYRN-SOFGYWHQSA-N O=C(O)/C=C/c1ccc(-c2ccccc2Cl)o1 Chemical compound O=C(O)/C=C/c1ccc(-c2ccccc2Cl)o1 IZITWMKBFNBYRN-SOFGYWHQSA-N 0.000 description 1
- HAGYDVODCYJMBX-GQCTYLIASA-N O=C(O)/C=C/c1ccc(-c2cccs2)o1 Chemical compound O=C(O)/C=C/c1ccc(-c2cccs2)o1 HAGYDVODCYJMBX-GQCTYLIASA-N 0.000 description 1
- WGIROCSDYHZQIG-UHFFFAOYSA-N O=C(O)C1SCCN1c1ccccc1 Chemical compound O=C(O)C1SCCN1c1ccccc1 WGIROCSDYHZQIG-UHFFFAOYSA-N 0.000 description 1
- 0 O=C(O)C:Cc1ccc(-c2cccs2)o1 Chemical compound O=C(O)C:Cc1ccc(-c2cccs2)o1 0.000 description 1
- BVLVACDKYXUCOA-UHFFFAOYSA-N O=C(O)CCC1=CC=C(c2ccccc2)C1 Chemical compound O=C(O)CCC1=CC=C(c2ccccc2)C1 BVLVACDKYXUCOA-UHFFFAOYSA-N 0.000 description 1
- AWWCHPQHDKVFCV-UHFFFAOYSA-N O=C(O)CCC1=CC=C(c2cccs2)C1 Chemical compound O=C(O)CCC1=CC=C(c2cccs2)C1 AWWCHPQHDKVFCV-UHFFFAOYSA-N 0.000 description 1
- CXEFZVVLTJQWBF-UHFFFAOYSA-N O=C(O)CCCOCc1ccccc1 Chemical compound O=C(O)CCCOCc1ccccc1 CXEFZVVLTJQWBF-UHFFFAOYSA-N 0.000 description 1
- KQWSLARKDDVGJR-UHFFFAOYSA-N O=C(O)CCN1CCC(c2ccccc2)=N1 Chemical compound O=C(O)CCN1CCC(c2ccccc2)=N1 KQWSLARKDDVGJR-UHFFFAOYSA-N 0.000 description 1
- PEMSGNPALUHKCC-UHFFFAOYSA-N O=C(O)CCc1ccc(-c2ccc(F)cc2)o1 Chemical compound O=C(O)CCc1ccc(-c2ccc(F)cc2)o1 PEMSGNPALUHKCC-UHFFFAOYSA-N 0.000 description 1
- JKBUDDSGMWGQDN-UHFFFAOYSA-N O=C(O)CCc1ccc(-c2ccccc2)o1 Chemical compound O=C(O)CCc1ccc(-c2ccccc2)o1 JKBUDDSGMWGQDN-UHFFFAOYSA-N 0.000 description 1
- UBSBRLFVQKHLPG-UHFFFAOYSA-N O=C(O)CCc1nc(-c2ccccc2)no1 Chemical compound O=C(O)CCc1nc(-c2ccccc2)no1 UBSBRLFVQKHLPG-UHFFFAOYSA-N 0.000 description 1
- OOHZXPIDNZNTAY-UHFFFAOYSA-N O=C(O)CCc1nc(-c2ccccc2F)no1 Chemical compound O=C(O)CCc1nc(-c2ccccc2F)no1 OOHZXPIDNZNTAY-UHFFFAOYSA-N 0.000 description 1
- JLFDJAGKPSZXGN-UHFFFAOYSA-N O=C(O)CCc1ncc(-c2ccc(Br)cc2)o1 Chemical compound O=C(O)CCc1ncc(-c2ccc(Br)cc2)o1 JLFDJAGKPSZXGN-UHFFFAOYSA-N 0.000 description 1
- XKDNEJYXLSVRMO-UHFFFAOYSA-N O=C(O)CCc1ncc(-c2ccc(Cl)cc2)o1 Chemical compound O=C(O)CCc1ncc(-c2ccc(Cl)cc2)o1 XKDNEJYXLSVRMO-UHFFFAOYSA-N 0.000 description 1
- GFVIYHMHRMUSLA-UHFFFAOYSA-N O=C(O)CCc1ncc(-c2ccccc2)o1 Chemical compound O=C(O)CCc1ncc(-c2ccccc2)o1 GFVIYHMHRMUSLA-UHFFFAOYSA-N 0.000 description 1
- CUYMDSTYUZAYFH-UHFFFAOYSA-N O=C(O)CCc1nnc(-c2ccccc2)o1 Chemical compound O=C(O)CCc1nnc(-c2ccccc2)o1 CUYMDSTYUZAYFH-UHFFFAOYSA-N 0.000 description 1
- WBDKMRXSDHJUOG-UHFFFAOYSA-N O=C(O)CCn1nc(-c2ccc(Cl)cc2)ccc1=O Chemical compound O=C(O)CCn1nc(-c2ccc(Cl)cc2)ccc1=O WBDKMRXSDHJUOG-UHFFFAOYSA-N 0.000 description 1
- NZCWSVNDWPYQNJ-UHFFFAOYSA-N O=C(O)CCn1nc(-c2ccc(F)cc2)ccc1=O Chemical compound O=C(O)CCn1nc(-c2ccc(F)cc2)ccc1=O NZCWSVNDWPYQNJ-UHFFFAOYSA-N 0.000 description 1
- NZUXPNSGLKNCQR-UHFFFAOYSA-N O=C(O)CCn1nc(-c2ccccc2)ccc1=O Chemical compound O=C(O)CCn1nc(-c2ccccc2)ccc1=O NZUXPNSGLKNCQR-UHFFFAOYSA-N 0.000 description 1
- IHKNZQHGINFJJV-UHFFFAOYSA-N O=C(O)COc1cccc(-n2cnnn2)c1 Chemical compound O=C(O)COc1cccc(-n2cnnn2)c1 IHKNZQHGINFJJV-UHFFFAOYSA-N 0.000 description 1
- TXVPLTOTVAGBDN-UHFFFAOYSA-N O=C(O)CSc1nc(-c2ccccc2)cs1 Chemical compound O=C(O)CSc1nc(-c2ccccc2)cs1 TXVPLTOTVAGBDN-UHFFFAOYSA-N 0.000 description 1
- VKPCKQCSWWCRFI-UHFFFAOYSA-N O=C(O)CSc1nnc(-c2ccccc2)o1 Chemical compound O=C(O)CSc1nnc(-c2ccccc2)o1 VKPCKQCSWWCRFI-UHFFFAOYSA-N 0.000 description 1
- YOLXEINPQBNDGH-UHFFFAOYSA-N O=C(O)Cc1ccc(-c2cccs2)o1 Chemical compound O=C(O)Cc1ccc(-c2cccs2)o1 YOLXEINPQBNDGH-UHFFFAOYSA-N 0.000 description 1
- UNFZKRKCIQJNKV-UHFFFAOYSA-N O=C(O)Cc1ccn(CC(F)(F)F)n1 Chemical compound O=C(O)Cc1ccn(CC(F)(F)F)n1 UNFZKRKCIQJNKV-UHFFFAOYSA-N 0.000 description 1
- LRBQNJMCXXYXIU-SDLUEIRESA-N O=C(OC[C@H]1OC(OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)C(OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)C1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1 Chemical compound O=C(OC[C@H]1OC(OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)C(OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)C1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1 LRBQNJMCXXYXIU-SDLUEIRESA-N 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N O=C(OC[C@H]1O[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1 Chemical compound O=C(OC[C@H]1O[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- BXNWJCZJEZDFCY-UHFFFAOYSA-M O=C([Na+])c1ccccc1-c1c2cc(Br)c(=O)cc-2oc2c([Hg]O)c([Na+])c(Br)cc12.O=O.O=O Chemical compound O=C([Na+])c1ccccc1-c1c2cc(Br)c(=O)cc-2oc2c([Hg]O)c([Na+])c(Br)cc12.O=O.O=O BXNWJCZJEZDFCY-UHFFFAOYSA-M 0.000 description 1
- ADIPPCCQUCTDJD-UHFFFAOYSA-M O=C([O-])CCc1ccc(-c2cccs2)o1 Chemical compound O=C([O-])CCc1ccc(-c2cccs2)o1 ADIPPCCQUCTDJD-UHFFFAOYSA-M 0.000 description 1
- WOZJGFBFMIWEGN-UHFFFAOYSA-M O=C([O-])CSc1ccc2ccccc2n1 Chemical compound O=C([O-])CSc1ccc2ccccc2n1 WOZJGFBFMIWEGN-UHFFFAOYSA-M 0.000 description 1
- OHCFGBLQZMYRTR-UHFFFAOYSA-K O=C([O-])c1ccccc1-c1c2cc(Br)c(=O)cc-2oc2c([Hg]O)c([O-])c(Br)cc12.[Na+].[Na+] Chemical compound O=C([O-])c1ccccc1-c1c2cc(Br)c(=O)cc-2oc2c([Hg]O)c([O-])c(Br)cc12.[Na+].[Na+] OHCFGBLQZMYRTR-UHFFFAOYSA-K 0.000 description 1
- NVBSISRLNAAAEQ-CMDGGOBGSA-N O=[N+]([O-])/C=C/c1ccc(-c2ccccc2)o1 Chemical compound O=[N+]([O-])/C=C/c1ccc(-c2ccccc2)o1 NVBSISRLNAAAEQ-CMDGGOBGSA-N 0.000 description 1
- OEPXXZAIQFTFHD-UHFFFAOYSA-N O=[N+]([O-])c1ccc2cn(-c3ccccc3)nc2c1 Chemical compound O=[N+]([O-])c1ccc2cn(-c3ccccc3)nc2c1 OEPXXZAIQFTFHD-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/305—Mercury compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
Definitions
- This invention relates to inhibitors of UDP-glucose dehydrogenase, and more particularly to UDP-glucose dehydrogenase inhibitors that are useful in the treatment of prostate cancer.
- Prostate cancer is the most frequently diagnosed cancer among men in the United States, and the second most frequent cause of cancer death.
- One of the first line treatments for inoperable or locally advanced cancers is androgen deprivation therapy, since the cells of the prostate normally depend on circulating androgen hormones for survival. This treatment fails in approximately 20% of cases treated this way, and leads to even more aggressive cancer, termed castration resistant prostate cancer (CRPC).
- CRPC castration resistant prostate cancer
- the present application provides, inter alia, a method of treating prostate cancer, comprising administering to a patient in need thereof a therapeutically effective amount of a compound provided in Table 1, or a pharmaceutically acceptable salt thereof.
- the prostate cancer is castration resistant prostate cancer (CRPC).
- CRPC castration resistant prostate cancer
- the compound is administered in combination with one or more additional therapies.
- at least one of the one or more additional therapies comprises administration of a chemotherapeutic agent.
- at least one of the one or more additional therapeutic agents comprises androgen deprivation therapy.
- the compound is administered prior to the one or more additional therapies.
- the compound is 2,2′-[1-(4-amino-1,2,5-oxadiazol-3-yl)-1H-1,2,3-triazole-4,5-diyl]di(2-butanol) (1), or a pharmaceutically acceptable salt thereof.
- the compound is 3-[5-(2-thienyl)-2-furyl]propanoic acid (31), or a pharmaceutically acceptable salt thereof.
- the present application further provides a method of modulating an activity of UDP-glucose dehydrogenase (UGDH) in a cell, the method comprising contacting the cell with an effective amount of a compound provided in Table 1, or a pharmaceutically acceptable salt thereof.
- UGDH UDP-glucose dehydrogenase
- the modulating an activity of UDP-glucose dehydrogenase comprises inhibiting UDP-glucose dehydrogenase (UGDH).
- the compound is 2,2′-[1-(4-amino-1,2,5-oxadiazol-3-yl)-1H-1,2,3-triazole-4,5-diyl]di(2-butanol) (1), or a pharmaceutically acceptable salt thereof.
- the compound is 3-[5-(2-thienyl)-2-furyl]propanoic acid (31), or a pharmaceutically acceptable salt thereof.
- the present application further provides a method of treating a prostate cancer mediated by UDP-glucose dehydrogenase (UGDH) in a patient in need thereof, the method comprising administering a therapeutically effective amount of a compound provided in Table 1, or a pharmaceutically acceptable salt thereof.
- UGDH UDP-glucose dehydrogenase
- the prostate cancer is castration resistant prostate cancer (CRPC).
- CRPC castration resistant prostate cancer
- the compound is 2,2′-[1-(4-amino-1,2,5-oxadiazol-3-yl)-1H-1,2,3-triazole-4,5-diyl]di(2-butanol) (1), or a pharmaceutically acceptable salt thereof.
- the compound is 3-[5-(2-thienyl)-2-furyl]propanoic acid (31), or a pharmaceutically acceptable salt thereof.
- the present application further provides a method of predicting patient response to prostate cancer therapy, comprising:
- the biopsy sample comprises prostate cancer cells and non-cancerous tissue cells
- UDP-glucose dehydrogenase (UGDH) expression is greater in the prostate cancer cells compared to the UDP-glucose dehydrogenase (UGDH) expression in the non-cancerous tissue cells, then the patient is more likely to respond to the prostate cancer therapy.
- the prostate cancer is castration resistant prostate cancer (CRPC).
- CRPC castration resistant prostate cancer
- the comparing comprises determining the ratio of UDP-glucose dehydrogenase (UGDH) expression in the prostate cancer cells and UDP-glucose dehydrogenase (UGDH) expression in the non-cancerous tissue cells.
- UGDH UDP-glucose dehydrogenase
- the prostate cancer therapy comprises androgen deprivation therapy. In some embodiments, the prostate cancer therapy is androgen deprivation therapy.
- the present application further provides a method of treating a prostate cancer mediated by UDP-glucose dehydrogenase (UGDH) in a patient in need thereof, the method comprising:
- the biopsy sample comprises prostate cancer cells and non-cancerous tissue cells
- the comparing comprises determining the ratio of UDP-glucose dehydrogenase (UGDH) expression in the prostate cancer cells and UDP-glucose dehydrogenase (UGDH) expression in the non-cancerous tissue cells.
- UGDH UDP-glucose dehydrogenase
- the prostate cancer is castration resistant prostate cancer (CRPC).
- CRPC castration resistant prostate cancer
- the method further comprises administration of one or more additional therapies.
- at least one of the one or more additional therapies comprises administration of a chemotherapeutic agent.
- at least one of the one or more additional therapeutic agents comprises administration of androgen deprivation therapy.
- the compound is 2,2′-[1-(4-amino-1,2,5-oxadiazol-3-yl)-1H-1,2,3-triazole-4,5-diyl]di(2-butanol) (1), or a pharmaceutically acceptable salt thereof.
- the compound is 3-[5-(2-thienyl)-2-furyl]propanoic acid (31), or a pharmaceutically acceptable salt thereof.
- the present application further provides a method of improving the efficacy of androgen deprivation therapy in a patient, comprising administering to the patient a therapeutically effective amount of a UDP-glucose dehydrogenase (UGDH) inhibitor.
- UGDH UDP-glucose dehydrogenase
- the androgen deprivation therapy is administered for the treatment of prostate cancer in the patient.
- the prostate cancer is castration resistant prostate cancer (CRPC).
- the UDP-glucose dehydrogenase (UGDH) inhibitor is selected from a compound provided in Table 1, or a pharmaceutically acceptable salt thereof.
- the compound is 2,2′-[1-(4-amino-1,2,5-oxadiazol-3-yl)-1H-1,2,3-triazole-4,5-diyl]di(2-butanol) (1), or a pharmaceutically acceptable salt thereof.
- the compound is 3-[5-(2-thienyl)-2-furyl]propanoic acid (31), or a pharmaceutically acceptable salt thereof.
- FIG. 1 shows a Gantt chart providing representative timing of the assay of Example 1.
- FIG. 2 is a diagram showing a mechanism wherein UGDH provides precursors for androgen inactivation by UGT-mediated glucuronidation.
- FIGS. 3A-3C shows results of a simulated androgen deprivation therapy assay.
- FIG. 4 shows modulation of function of AR using a luciferase reporter assay driven by the AR-stimulated PSA promoter/enhancer region.
- FIG. 5A is a diagram showing a mechanism wherein UGDH loss of activity may allow cells to sustain sensitivity to androgen deprivation.
- FIG. 5B shows data wherein UGDH knockdown lowers steroid dose required for AR gene expression.
- FIGS. 6A-6B shows a mixed-model inhibition fit for UDP-xylose used for determination of K i .
- FIG. 7A-7E show kinetic characterization of inhibitors (1) (i.e. 5210344) and (31) (i.e., 6847944).
- FIGS. 8A-8D show UDP-xylose effects on the thermal stability of WT, T325A (inducible hexamer), and T325D (obligate dimer) UGDH.
- FIGS. 9A-9D shows inhibitor (1) effects on the thermal stability of WT, T325A (inducible hexamer), and T325D (obligate dimer) UGDH.
- FIG. 10A-10C shows inhibitor (31) effects on the thermal stability of WT, T325A (inducible hexamer), and T325D (obligate dimer) UGDH.
- FIG. 11 shows UDP-xylose stabilizing UGDH T325A and T325D mutants against limited trypsin proteolysis.
- FIG. 12 illustrates the effects of inhibitor (1) and (31) on trypsin digestion of WT and mutant UGDH.
- UDP-glucose dehydrogenase catalyzes the NAD + -dependent, two-step oxidation of UDP-glucose to UDP-glucuronic acid, an essential precursor for hyaluronan synthesis by HAS enzymes, other glycosaminoglycan/proteoglycan production in the Golgi, and glucuronidation of steroid hormones by UGTs for solubilization and excretion (see, e.g., Prydz et al., J. Cell Sci. 2000, 113, 193-205; Fraser et al., J. Intern. Med. 1997, 242, 27-33; Guillemette C., Pharmacogenomics J.
- UGDH expression is specific to the liver and prostate in males, and prostate tumor progression has been correlated with a loss of UGDH regulation. Accordingly, the present application provides inhibitors of UGDH that are useful in the treatment of prostate cancer and methods for predicting the efficacy of androgen deprivation therapy.
- a “therapeutically effective amount” of a conjugate with respect to the subject method of treatment refers to an amount of the conjugate(s) in a preparation which, when administered as part of a desired dosage regimen (to a patient, e.g., a human) alleviates a symptom, ameliorates a condition, or slows the onset of disease conditions according to clinically acceptable standards for the disorder or condition to be treated or the cosmetic purpose, e.g., at a reasonable benefit/risk ratio applicable to any medical treatment.
- treating includes reversing, reducing, or arresting the symptoms, clinical signs, and underlying pathology of a condition in manner to improve or stabilize a patient's condition.
- the present application provides, inter alia, compounds that are useful as UDP-glucose dehydrogenase (UGDH) inhibitors.
- the compound is 2,2′-[1-(4-amino-1,2,5-oxadiazol-3-yl)-1H-1,2,3-triazole-4,5-diyl]di(2-butanol) (1), or a pharmaceutically acceptable salt thereof.
- the compound is 3-[5-(2-thienyl)-2-furyl]propanoic acid (31), or a pharmaceutically acceptable salt thereof.
- the compound 2,2′-[1-(4-amino-1,2,5-oxadiazol-3-yl)-1H-1,2,3-triazole-4,5-diyl]di(2-butanol) (1) is also referred to as inhibitor 5210344.
- the compound 3-[5-(2-thienyl)-2-furyl]propanoic acid (31) is also referred to as inhibitor 6847944.
- a compound is selected from the group provided in Table 1.
- the present application further provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound provided herein (e.g., a compound provided in Table 1), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
- the pharmaceutical composition comprises 2,2′-[1-(4-amino-1,2,5-oxadiazol-3-yl)-1H-1,2,3-triazole-4,5-diyl]di(2-butanol) (1), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
- the pharmaceutical composition comprises 3-[5-(2-thienyl)-2-furyl]propanoic acid (31), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
- the compounds provided herein can be administered in the form of pharmaceutical compositions; thus, the methods described herein can include administering pharmaceutical compositions provided herein.
- compositions can be prepared as described herein or elsewhere, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated.
- Administration may be pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral, or parenteral.
- Parenteral administration may include, but is not limited to intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular injection or infusion; or intracranial, (e.g., intrathecal, intraocular, or intraventricular) administration.
- Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump.
- Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
- the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container.
- an excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
- compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
- excipients include, without limitation, lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose.
- the formulations can additionally include, without limitation, lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; flavoring agents, or combinations thereof.
- the active compounds can be effective over a wide dosage range and are generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered and the schedule of administration will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual subject, the severity of the subject's symptoms, and the like.
- the present application further provides methods of treating prostate cancer in a patient in need thereof.
- the term “patient” refers to any animal, including mammals, for example, mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, primates, and humans.
- the patient is a human.
- the method comprises administering to the patient a therapeutically effective amount of a compound provided herein (e.g., a compound provided in Table 1), or a pharmaceutically acceptable salt thereof.
- the compound is 2,2′-[1-(4-amino-1,2,5-oxadiazol-3-yl)-1H-1,2,3-triazole-4,5-diyl]di(2-butanol) (1), or a pharmaceutically acceptable salt thereof.
- the compound is 3-[5-(2-thienyl)-2-furyl]propanoic acid (31), or a pharmaceutically acceptable salt thereof.
- the prostate cancer comprises a cancer selected from the group consisting of acinar adenocarcinoma, atropic adenocarcinoma, foamy adenocarcinoma, colloid adenocarcinoma, signet ring carcinoma, ductal adenocarcinoma transitional cell (or urothelial) cancer, squamous cell cancer, carcinoid, small cell cancer, sarcoma cancer, sarcomatoid cancer, and castration resistant prostate cancer (CRPC).
- the prostate cancer is castration resistant prostate cancer (CRPC).
- a compound provided herein e.g., a compound provided in Table 1
- a pharmaceutically acceptable salt thereof is administered in combination with one or more additional therapies.
- at least one of the one or more additional therapies is selected from the group consisting of administration of a chemotherapeutic agent, radiation therapy, a surgical procedure, androgen deprivation therapy, or any combination thereof.
- at least one of the one or more additional therapies comprises administration of at least one chemotherapeutic agent.
- at least one of the one or more additional therapies comprises androgen deprivation therapy.
- at least one of the one or more additional therapies is androgen deprivation therapy.
- a compound provided herein, or a pharmaceutically acceptable salt thereof is administered prior to the one or more additional therapies. In some embodiments, a compound provided herein, or pharmaceutically acceptable salt thereof, is administered concurrently with the one or more additional therapies. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered after the one or more additional therapies.
- the compound is 2,2′-[1-(4-amino-1,2,5-oxadiazol-3-yl)-1H-1,2,3-triazole-4,5-diyl]di(2-butanol) (1), or a pharmaceutically acceptable salt thereof, and at least one of the one or more additional therapies is androgen deprivation therapy.
- the compound is 3-[5-(2-thienyl)-2-furyl]propanoic acid (31), or a pharmaceutically acceptable salt thereof, and at least one of the one or more additional therapies is androgen deprivation therapy.
- the method comprises:
- the method comprises:
- the present application further provides a method of modulating an activity of UDP-glucose dehydrogenase (UGDH) in a cell, the method comprising contacting the cell with an effective amount of a compound provided herein (e.g., a compound provided in Table 1), or a pharmaceutically acceptable salt thereof.
- the modulating an activity of UDP-glucose dehydrogenase (UGDH) comprises inhibiting UDP-glucose dehydrogenase (UGDH).
- the compound is 2,2′-[1-(4-amino-1,2,5-oxadiazol-3-yl)-1H-1,2,3-triazole-4,5-diyl]di(2-butanol) (1), or a pharmaceutically acceptable salt thereof.
- the compound is 3-[5-(2-thienyl)-2-furyl]propanoic acid (31), or a pharmaceutically acceptable salt thereof.
- the present application further provides a method of treating a prostate cancer mediated by UDP-glucose dehydrogenase (UGDH) in a patient in need thereof, the method comprising administering a therapeutically effective amount of a compound provided herein (e.g., a compound provided in Table 1), or a pharmaceutically acceptable salt thereof.
- UGDH UDP-glucose dehydrogenase
- the prostate cancer comprises a cancer selected from the group consisting of acinar adenocarcinoma, atropic adenocarcinoma, foamy adenocarcinoma, colloid adenocarcinoma, signet ring carcinoma, ductal adenocarcinoma transitional cell (or urothelial) cancer, squamous cell cancer, carcinoid, small cell cancer, sarcoma cancer, sarcomatoid cancer, and castration resistant prostate cancer (CRPC).
- the prostate cancer is castration resistant prostate cancer (CRPC).
- the compound is 2,2′-[1-(4-amino-1,2,5-oxadiazol-3-yl)-1H-1,2,3-triazole-4,5-diyl]di(2-butanol) (1), or a pharmaceutically acceptable salt thereof.
- the compound is 3-[5-(2-thienyl)-2-furyl]propanoic acid (31), or a pharmaceutically acceptable salt thereof.
- the present application further provides a method of predicting patient response to prostate cancer therapy, comprising:
- the biopsy sample comprises prostate cancer cells and non-cancerous tissue cells
- the prostate cancer cells comprise a prostate cancer selected from the group consisting of acinar adenocarcinoma cells, atropic adenocarcinoma cells, foamy adenocarcinoma cells, colloid adenocarcinoma cells, signet ring carcinoma cells, ductal adenocarcinoma transitional cell (or urothelial) cancer cells, squamous cell cancer cells, carcinoid cells, small cell cancer cells, sarcoma cancer cells, sarcomatoid cancer cells, and castration resistant prostate cancer (CRPC) cells.
- the prostate cancer cells comprise castration resistant prostate cancer (CRPC) cells.
- the prostate cancer is castration resistant prostate cancer (CRPC).
- non-cancerous tissue cells refers to non-cancerous tissue cells in the area surrounding the prostate cancer cells.
- non-cancerous tissue cells may refer to non-cancerous prostate tissue cells, non-cancerous acini, and normal-appearing acini (NAA).
- NAA normal-appearing acini
- the non-cancerous or normal-appearing acini are selected from the group consisting of acini of the stomach, acini of the sebaceous gland of the scalp, acini of the liver, acini of the lung, acini of the lacrimal gland, acini of mammary gland, acini of the pancreas, and acini of the prostate.
- the non-cancerous tissue cells comprise prostate tissue cells. In some embodiments, the non-cancerous tissue cells are prostate tissue cells. In some embodiments, the non-cancerous tissue cells comprise non-cancerous acini or normal-appearing acini (NAA). In some embodiments, the non-cancerous cells comprise normal-appearing acini. Examples of normal-appearing acini that may be used in the method provided herein may be found, for example, in Huang et al., Int. J. Cancer, 2010, 126(5), 315-327, the disclosure of which is incorporated herein in its entirety.
- the comparing comprises determining the ratio of UDP-glucose dehydrogenase (UGDH) expression in the prostate cancer cells and UDP-glucose dehydrogenase (UGDH) expression in the non-cancerous tissue cells. In some embodiments, the comparing comprises:
- the quantifying comprises determining the average mean pixel intensity acini within the prostate cancer cells and acini within the non-cancerous tissue cells (e.g., non-cancerous acini or normal-appearing acini (NAA)).
- acini within the non-cancerous tissue cells e.g., non-cancerous acini or normal-appearing acini (NAA)
- the patient is more likely to respond to prostate cancer therapy when the average mean pixel intensity of acini within the prostate cancer cells is at least about 10% greater than the average mean pixel intensity of acini within the non-cancerous tissue cells (e.g., non-cancerous acini or normal-appearing acini (NAA)), for example, at least about 10%, at least about 15% at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 100%.
- non-cancerous tissue cells e.g., non-cancerous acini or normal-appearing acini (NAA)
- NAA normal-appearing acini
- the patient is more likely to respond to prostate cancer therapy when the average mean pixel intensity of acini within the prostate cancer cells is at least about 15% greater than the average mean pixel intensity of acini within the non-cancerous tissue cells (e.g., non-cancerous acini or normal-appearing acini (NAA)).
- non-cancerous tissue cells e.g., non-cancerous acini or normal-appearing acini (NAA)
- the prostate cancer therapy is selected from the group consisting of administration of a chemotherapeutic agent, radiation therapy, a surgical procedure, androgen deprivation therapy, or any combination thereof.
- a compound provided herein e.g., a compound provided in Table 1
- a compound provided herein, or pharmaceutically acceptable salt thereof is administered prior to the prostate cancer therapy.
- a compound provided herein, or pharmaceutically acceptable salt thereof is administered concurrently with the prostate cancer therapy.
- a compound provided herein, or a pharmaceutically acceptable salt thereof is administered after the prostate cancer therapy.
- the prostate cancer therapy comprises administration of at least one chemotherapeutic agent.
- the prostate cancer therapy comprises androgen deprivation therapy.
- the prostate cancer therapy is androgen deprivation therapy.
- the present application further provides a method of treating a prostate cancer mediated by UDP-glucose dehydrogenase (UGDH) in a patient in need thereof, the method comprising:
- the biopsy sample comprises prostate cancer cells and non-cancerous tissue cells
- a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof administering a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof.
- UGDH UDP-glucose dehydrogenase
- the prostate cancer is determined to be associated with one or more of overexpression and amplification of UDP-glucose dehydrogenase (UGDH) in the prostate cancer cells compared to the non-cancerous tissue cells when the average mean pixel intensity of acini within the prostate cancer cells is at least about 10% greater than the average mean pixel intensity of acini within the non-cancerous tissue cells (e.g., non-cancerous acini or normal-appearing acini (NAA)), for example, at least about 10%, at least about 15% at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 100%.
- UGDH UDP-glucose dehydrogenase
- the patient is more likely to respond to prostate cancer therapy when the average mean pixel intensity of acini within the prostate cancer cells is at least about 15% greater than the average mean pixel intensity of acini within the non-cancerous tissue cells (e.g., non-cancerous acini or normal-appearing acini (NAA)).
- non-cancerous tissue cells e.g., non-cancerous acini or normal-appearing acini (NAA)
- the prostate cancer is determined to be associated with one or more of overexpression and amplification of UDP-glucose dehydrogenase (UGDH) in the prostate cancer cells compared to the non-cancerous tissue cells when the expression of UGDH within the prostate cancer cells is at least about 10% greater than the expression of UGDH within the non-cancerous tissue cells (e.g., non-cancerous acini or normal-appearing acini (NAA)), for example, at least about 10%, at least about 15% at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 100%.
- UGDH UDP-glucose dehydrogenase
- the patient is more likely to respond to prostate cancer therapy when the expression of UGDH is within the prostate cancer cells is at least about 15% greater than the expression of UGDH within the non-cancerous tissue cells (e.g., non-cancerous acini or normal-appearing acini (NAA)).
- non-cancerous tissue cells e.g., non-cancerous acini or normal-appearing acini (NAA)
- the method further comprises administration of one or more additional therapies.
- at least one of the one or more additional therapies is selected from the group consisting of administration of a chemotherapeutic agent, radiation therapy, a surgical procedure, androgen deprivation therapy, or any combination thereof.
- at least one of the one or more additional therapies administering at least one chemotherapeutic agent.
- at least one of the one or more additional therapies comprises androgen deprivation therapy.
- at least one of the one or more additional therapies is androgen deprivation therapy.
- a compound provided herein e.g., a compound provided in Table 1
- a compound provided herein, or pharmaceutically acceptable salt thereof is administered prior to the one or more additional therapies.
- a compound provided herein, or pharmaceutically acceptable salt thereof is administered concurrently with the one or more additional therapies.
- a compound provided herein, or a pharmaceutically acceptable salt thereof is administered after the one or more additional therapies.
- the compound is 2,2′-[1-(4-amino-1,2,5-oxadiazol-3-yl)-1H-1,2,3-triazole-4,5-diyl]di(2-butanol) (1), or a pharmaceutically acceptable salt thereof.
- the compound is 3-[5-(2-thienyl)-2-furyl]propanoic acid (31), or a pharmaceutically acceptable salt thereof.
- the present application further provides a method of improving the efficacy of androgen deprivation therapy in a patient, comprising administering to the patient a therapeutically effective amount of a UDP-glucose dehydrogenase (UGDH) inhibitor.
- UGDH UDP-glucose dehydrogenase
- the prostate cancer comprises a cancer selected from the group consisting of acinar adenocarcinoma, atropic adenocarcinoma, foamy adenocarcinoma, colloid adenocarcinoma, signet ring carcinoma, ductal adenocarcinoma transitional cell (or urothelial) cancer, squamous cell cancer, carcinoid, small cell cancer, sarcoma cancer, sarcomatoid cancer, and castration resistant prostate cancer (CRPC).
- the prostate cancer is castration resistant prostate cancer (CRPC).
- the UDP-glucose dehydrogenase (UGDH) inhibitor is selected from a compound provided herein (e.g., a compound provided in Table 1), or a pharmaceutically acceptable salt thereof.
- the compound is 2,2′-[1-(4-amino-1,2,5-oxadiazol-3-yl)-1H-1,2,3-triazole-4,5-diyl]di(2-butanol) (1), or a pharmaceutically acceptable salt thereof.
- the compound is 3-[5-(2-thienyl)-2-furyl]propanoic acid (31), or a pharmaceutically acceptable salt thereof.
- UDP-glucose (MW 610), Sigma U4625 Stock 100 mM in water Stored at ⁇ 20°. Do not refreeze.
- BSA Meso Scale Discovery, Blocker A, catalog# R93BA-1 Stock 5.6% in PBS (W/V).
- Preparation of 1 liter Prepare enzyme in polypropylene. Do not let enzyme touch glass or polystyrene. Because the enzyme is the least stable of all reagents used in the assay, it should be prepared last. Enzyme buffer should be kept cold if any time passes before use.
- FIG. 1 provides a gantt chart which shows how the assay timing would work.
- Table 3 shows POC values for compounds screened in the high throughput assay.
- FIG. 2 shows a diagram of UGDH providing precursors for androgen inactivation by UGT-mediated glucuronidation.
- UGDH UGDH
- FIG. 3 AR promoter binding was modulated, so we further confirmed modulation of the AR using a luciferase reporter assay driven by the AR-stimulated PSA promoter/enhancer region, as shown in FIG. 4 .
- FIG. 5A-5B shows that a loss of activity of UGDH may allow cells to sustain sensitivity to androgen deprivation.
- T325A and T325D are engineered inducible hexameric and obligate dimeric UGDH species, respectively.
- Table 5 shows inhibition data for UDP-xylose, inhibitor (1) (i.e., 5210344), and inhibitor (31) (i.e., 6847944).
- IC 50 values for UDP-xylose and inhibitor (1) were determined using Km concentrations of UDP-glucose and NAD+ (50 ⁇ M UDP-glc and 1 mM NAD + ). Ki values were determined by varying [UDP-glc] and holding NAD+ at saturating concentrations.
- UDP-xylose is a more potent inhibitor than the other compounds.
- Inhibitor (1) may have greatest effect on the dimer.
- Inhibitor (31) appears to require the ability for hexamer formation to inhibit which may suggest interference at the dimer-dimer interface as mechanism of action.
- FIGS. 6A-6B show a mixed-model inhibition fit for UDP-xylose used for determination of K i .
- IC 50 curve was performed as described above (see, e.g., Example 2) and was found to be 0.58 ⁇ 0.09 ⁇ M.
- FIG. 7A-7E show kinetic characterization of inhibitors (1) and (31).
- IC 50 experiments were performed as described above (see e.g., Example 2). Calculated IC 50 and K i values can be found in Table 5.
- Inhibitor (1) did not show inhibition in the WT K curve, but did with T325A which may support requirement of the dimer for inhibition.
- Inhibitor (31) is an allosteric inhibitor that may bind in the dimer-dimer interface or alter the interface to disrupt hexamer formation and inhibit the enzyme.
- FIG. 8A-8D show UDP-xylose effects on the thermal stability of WT, T325A (inducible hexamer), and T325D (obligate dimer) UGDH.
- the UDP-xylose inhibitor triggered multiple unfolding events of UGDH, and increased the thermal stability of apo WT and T325A, similarly to the effect of the UDP-sugar substrate and cofactor.
- UDP-xylose appears to significantly increase thermal stability of NAD+ complexes with WT, T325A, and T325D, similarly to the effect of the productive holo complexes.
- Statistical analyses were performed using a two-way ANOVA with Bonferroni post tests on PRISM.
- FIG. 9A-9D shows inhibitor (1) (i.e., 5210344) effects on the thermal stability of WT, T325A (inducible hexamer), and T325D (obligate dimer) UGDH.
- the previously validated inhibitor appears to decrease thermal stability and cause multiple unfolding events of UDP-glcA complexes with WT, T325A, and T325D.
- This inhibitor also causes multiple unfolding events with the apo T325D and T325A mutants, which may indicate that this inhibitor can only bind to the dimeric form of UGDH in order to affect activity (supports the high IC 50 value with WT-UGDH).
- Inhibitor (31) has Negligible Effect on Thermal Stability
- FIG. 10A-10C shows inhibitor (31) (i.e., 6847944) effects on the thermal stability of WT, T325A (inducible hexamer), and T325D (obligate dimer) UGDH. This modestly affects the T325A and T325D mutants by decreasing thermal stability of all binary complexes except UDP-glucose.
- UDP-xylose stabilizes UGDH T325A and T325D mutants against limited trypsin proteolysis, as shown in FIG. 11 .
- UDP-xylose [20 ⁇ M] protected T325A apo from trypsin digestion (red star) and only slightly affected the other forms.
- UDP-xylose [20 ⁇ M] also significantly protected T325D complexes with NAD+, NADH, and UDP-glcA, but did not affect the apo and UDP-glc forms.
- Each assay contained 10 ⁇ g of enzyme, 10 ng Trypsin, and combinations of substrate, cofactor, and UDP-xylose, which was incubated 2.5 h, followed by SDS-PAGE.
- FIG. 12 shows inhibitor (1) and (31) effects on trypsin digestion of WT and mutant UGDH.
- Inhibitor (1) [750 ⁇ M] significantly affects trypsin digestion of T325A with UDP-glcA and UDP-glcA with NADH.
- 6847944 [500 ⁇ M] significantly affects ternary complexes for both WT and T325A. The same procedures from above (see e.g., Example 7) were followed.
Abstract
Description
TABLE 1 |
List of Compounds |
Compound | |||
| Name | Structure | |
1 | 2,2′-[1-(4-amino-1,2,5- oxadiazol-3- yl)-1H-1,2,3- triazole-4,5-diyl]di(2- butanol) |
|
2 | 2-[1-(4-amino-1,2,5- oxadiazol-3-yl)-5-(2- hydroxypropan-2-yl)- 1,2,3-triazol- 4-yl]propan- 2-ol |
|
3 | 1-[1-(4-amino-1,2,5- oxadiazol-3- yl)-5-methyl- 1,2,3-triazol- 4-yl]ethanol |
|
4 | [3-(4-amino-1,2,5- oxadiazol-3-yl)-1,2,3- triazol-4-yl]methanol |
|
5 | [1-(4-amino-1,2,5- oxadiazol-3- yl)-1H-1,2,3- triazol-4-yl]methanol |
|
6 | 1-[1-(4-amino-1,2,5- oxadiazol-3-yl)-1,2,3- triazol-4-yl]ethanol |
|
7 | 2-[1-(4-amino-1,2,5- oxadiazol-3-yl)-1,2,3- triazol-4-yl] propan-2-ol |
|
8 | 4-(5-ethyl-1,2,3- triazol-1-yl)- 1,2,5-oxadiazol-3- amine |
|
9 | methyl 1-(4- amino-1,2,5- oxadiazol-3-yl)-5-tert- butyl-1,2,3-triazole-4- carboxylate |
|
10 | methyl 1-(4- amino-1,2,5- oxadiazol-3- yl)-5-ethyl- 1,2,3-triazole-4- carboxylate |
|
11 | ethyl 1-(4- amino-1,2,5- oxadiazol-3- yl)-5-ethyl- 1,2,3-triazole-4- carboxylate |
|
12 | 1-(4-amino-1,2,5- oxadiazol-3- yl)-5-propyl- 1,2,3-triazole-4- carboxylic acid |
|
13 | tert-butyl 1-(4-amino- 1,2,5-oxadiazol- 3-yl)-5- methyl-1,2,3- triazole-4- carboxylate |
|
14 | isopropyl 1-(4-amino- 1,2,5-oxadiazol- 3-yl)-5- methyl-1,2,3- triazole-4- carboxylate |
|
15 | 1-(4-amino-1,2,5- oxadiazol-3-yl)-5- (methoxymethyl)-1H- 1,2,3-triazole-4- carboxylic acid |
|
16 | methyl 1-(4- amino-1,2,5- oxadiazol-3-yl)-5- (methoxymethyl)-1H- 1,2,3-triazole-4- carboxylate |
|
17 | 1-(4-amino-1,2,5- oxadiazol-3-yl)-5- [(dimethylamino) methyl]- 1,2,3-triazole-4- carboxylic acid |
|
18 | 1-(4-amino-1,2,5- oxadiazol-3- yl)-5-phenyl- 1,2,3-triazole-4- carboxylic acid |
|
19 | prop-2-en-1-yl 1-(4- amino-1,2,5- oxadiazol- yl)-5-methyl- 1H-1,2,3- triazole-4- carboxylate |
|
20 | 2-methoxyethyl 1-(4- amino-1,2,5- oxadiazol-3- yl)-5-methyl-1,2,3- triazole-4-carboxylate |
|
21 | ethyl 5- (adamantan-1-yl)- 1-(4-amino-1,2,5- oxadiazol-3- yl)-1H-1,2,3- triazole-4-carboxylate |
|
22 | (2R,2′S)-2,2′-(1-(4- amino-1,2,5- oxadiazol-3- yl)-1H-1,2,3- triazole-4,5- diyl)bis(butan-2-ol) |
|
23 | (S)-1-(1-(4- amino-1,2,5- oxadiazol-3- yl)-5-methyl- 1H-1,2,3-triazol-4- yl)ethanol |
|
24 | 2-[1-(4- amino-1,2,5- oxadiazol-3- yl)-1H-1,2,3- triazol-5-yl] propan-2-ol |
|
25 | [3-(4-amino-1,2,5- oxadiazol-3-yl)-5- (hydroxymethyl)- 1,2,3-triazol- 4-yl]methanol |
|
26 | 1-[3-(4-amino-1,2,5- oxadiazol- 3-yl)-1,2,3- triazol-4-yl]ethanol |
|
27 | 1-(4-amino-1,2,5- oxadiazol-3- yl)-5-tert- butyl-1,2,3- triazole-4- carboxylic acid |
|
28 | 1-(4-amino-1,2,5- oxadiazol-3-yl)-5- (propan-2-yl)- 1H-1,2,3- triazole-4- carboxylic acid |
|
29 | methyl 1-(4- amino-1,2,5- oxadiazol-3-yl)-5- isopropyl-1H-1,2,3- triazole-4- carboxylate |
|
30 | 1-(4-amino-1,2,5- oxadiazol-3-yl)-5-(4- methylphenyl)-1,2,3- triazole-4- carboxylic acid |
|
31 | 3-[5-(2-thienyl)-2- furyl]propanoic acid |
|
32 | N-methyl-N- phenylglycine hydrochloride |
|
33 | 3-(5-ethyl-2- thienyl)acrylic acid |
|
34 | 2-[(carboxymethyl) thio]-3-methyl-1,3- benzothiazol-3-ium bromide |
|
35 | 3-[5-(4- fluorophenyl)-2- furyl]acrylic acid |
|
36 | 3-phenyl-1,3- thiazolidine-2- carboxylic acid |
|
37 | 3-(5-phenyl-2- furyl)propanoic acid |
|
38 | 3-[5-(4- fluorophenyl)-2- furyl]propanoic acid |
|
39 | (E)-3-(5- phenylfuran-2- yl)prop-2-enoic acid |
|
40 | 3-(5-phenyl- 1,3-oxazol-2- yl)propanoic acid |
|
41 | 3-[5-(4-chlorophenyl)- 1,3-oxazol-2- yl]propanoic acid |
|
42 | 3-(5-phenyl-1,3,4- oxadiazol-2-yl) propanoic acid |
|
43 | 2-[(4-phenyl- 1,3-thiazol- 2-yl)sulfanyl] acetic acid |
|
44 | 3-[5-(4- bromophenyl)- 1,3-oxazol-2- yl]propanoic acid |
|
45 | 3-(5-thiophen- 2-yl-1H- pyrrol-2-yl) propanoic acid |
|
46 | 3-(5-phenyl-3,4- dihydropyrazol-2- yl)propanoic acid |
|
47 | (E)-3-[5-(2- chlorophenyl) furan-2- yl]prop-2- enoic acid |
|
48 | 2-[(E)-2- nitroethenyl]-5- phenylfuran |
|
49 | 3-(6-oxo-3- phenylpyridazin-1- yl)propanoic acid |
|
50 | 3-(3-phenyl-1,2,4- oxadiazol-5-yl) propanoic acid |
|
51 | 2-quinolin-2- ylsulfanylacetate |
|
52 | 2-[(5-phenyl-1,3,4- oxadiazol-2- yl)sulfanyl] acetic acid |
|
53 | 3-(5-phenyl- 1H-pyrrol-2- yl)propanoic acid |
|
54 | 3-[3-(4- chlorophenyl)-6- oxopyridazin-1- yl]propanoic acid |
|
55 | 3-[3-(4- fluorophenyl)-6- oxopyridazin-1- yl]propanoic acid |
|
56 | 2-[3-(tetrazol-1- yl)phenoxy]acetic acid |
|
57 | (E)-3-[5-(2- bromophenyl)furan-2- yl]prop-2-enoic acid |
|
58 | 4-phenyl- methoxybutanoic acid |
|
59 | 3-[3-(4- methylphenyl)-6- oxopyridazin-1- yl]propanoic acid |
|
60 | 3-[3-(2-fluorophenyl)- 1,2,4-oxadiazol-5- yl]propanoic acid |
|
61 | 6-nitro-2- phenylindazole |
|
62 | 2-[1-(2,2,2- trifluoroethyl) pyrazol-3- yl]acetic acid |
|
63 | 3-(5-thiophen- 2-ylfuran- 2-yl)propanoate |
|
64 | 3-(5-thiophen- 2-ylfuran- 2-yl)prop-2- enoic acid |
|
65 | methyl 3- (5-thiophen-2- ylfuran-2-yl) propanoate |
|
66 | (E)-3-(5-thiophen-2- ylfuran-2-yl) prop-2-enoic acid |
|
67 | 5-(5-methylfuran-2- yl)thiophene- 2-carboxylic acid |
|
68 | 2-(5-thiophen- 2-ylfuran- 2-yl)acetic acid |
|
69 | methyl 3- (5-thiophen-2- ylfuran-2-yl)prop-2- enoate |
|
70 | thiophen-2- ylmethyl 3- (furan-2-yl) propanoate |
|
71 |
|
|
72 |
|
|
73 |
|
|
74 |
|
|
75 |
|
|
76 |
|
|
77 |
|
|
78 |
|
|
79 |
|
|
80 |
|
|
81 |
|
|
82 |
|
|
83 |
|
|
84 |
|
|
85 |
|
|
86 |
|
|
87 |
|
|
88 |
|
|
89 |
|
|
90 |
|
|
91 |
|
|
92 |
|
|
93 |
|
|
94 |
|
|
95 |
|
|
96 |
|
|
97 |
|
|
98 |
|
|
99 |
|
|
100 |
|
|
101 |
|
|
102 |
|
|
103 |
|
|
104 |
|
|
105 |
|
|
106 |
|
|
107 |
|
|
108 |
|
|
109 |
|
|
110 |
|
|
111 |
|
|
112 |
|
|
113 |
|
|
114 |
|
|
115 |
|
|
116 |
|
|
117 |
|
|
118 |
|
|
119 |
|
|
120 |
|
|
121 |
|
|
122 |
|
|
123 |
|
|
124 |
|
|
125 |
|
|
126 |
|
|
127 |
|
|
128 |
|
|
129 |
|
|
130 |
|
|
131 |
|
|
132 |
|
|
133 |
|
|
134 |
|
|
135 |
|
|
136 |
|
|
137 |
|
|
138 |
|
|
139 |
|
|
140 |
|
|
141 |
|
|
142 |
|
|
143 |
|
|
144 |
|
|
145 |
|
|
146 |
|
|
147 |
|
|
148 |
|
|
149 |
|
|
150 |
|
|
151 |
|
|
152 |
|
|
153 |
|
|
154 |
|
|
155 |
|
|
156 |
|
|
157 |
|
|
158 |
|
|
159 |
|
|
160 |
|
|
161 |
|
|
162 |
|
|
163 |
|
|
164 |
|
|
165 |
|
|
166 |
|
|
167 |
|
|
168 |
|
|
169 |
|
|
170 |
|
|
UDP-glucose Dehydrogenase |
Stock 2.5 mg/ml |
Stored at −80°, as aliquots of 2 mL, don't refreeze |
Storage buffer: 20 mM Tris pH 7.4, 1 mM DTT |
NAD+ (MW = 663.4), |
Make |
50 mM stock in PBS fresh each day. |
Do not store overnight, even if frozen. |
UDP-glucose (MW = 610), |
Stock |
100 mM in water |
Stored at −20°. Do not refreeze. |
BSA, Meso Scale Discovery, Blocker A, catalog# R93BA-1 |
Stock 5.6% in PBS (W/V). |
Alliquot and store at −20° |
UDP-xylose, lot VX0707 (MW = 554.3), supplied by CaraboSource |
Services, CCRC/University of |
Stock |
1 mM in PBS |
Stored at −20°, as aliquots of 1 ml. Don't re-freeze |
DMSO (MW = 78.1), Fisher D136-1 |
PBS, pH 7.4, Sigma #P3813 |
Dissolve in 1 L water and store at room temp. |
NADH (MW = 742), |
Stock |
10 mM in PBS |
Store at −20° as aliquots of 100 μl. Do not re-freeze. |
ii. Cocktails
Enzyme Buffer 2.8×
-
- 1. 900 mL PBS;
- 2. 100 mL 5.6% BSA stock; and
- 3. 5.6 mL of 2500 μg/mL enzyme stock
Substrate Solution 2.8×
-
- 1. 1 liter PBS;
- 2. 14 mL of 50 mM NAD+ stock; and
- 3. 9.24 mL of 10 mM UDP-glucose stock or 924 μL of 100 mM UDP-glucose stock.
Positive Control Solution 3.5×
-
- 1. 97.5 mL PBS;
- 2. 2.5 mL DMSO; and
- 3. 7
mL 1 mM UDP-xylose stock
Negative Control Solution 3.5×
-
- 1. 97.5 mL PBS
- 2. 2.5 mL DMSO
Instruments and Lab-Equipment - 16-channel Finnpipette 5-50 μl
- 2 Thermo Scientific Multidrop 384 & cassettes.
- Tecan Safire2.
- Microtiterplates:
Greiner FLUOTRAC 200
iii. Methodology
-
- Plates are stored at −20° with 20 μL/well of 25 μg/mL compound in 2.5% DMSO in water.
- a. Dispense, with the 16channel Finnpipette, 20 μL of the negative control solution (2.5% DMSO) in
column 1. - b. Dispense, with the 16channel Finnpipette, 20 μL of the positive control solution (2.5% DMSO & 70 μM UDP-glucose) in
column 2.
- a. Dispense, with the 16channel Finnpipette, 20 μL of the negative control solution (2.5% DMSO) in
- Plates are stored at −20° with 20 μL/well of 25 μg/mL compound in 2.5% DMSO in water.
-
- a. Dispense, with the
Multidrop 384, 25 μL/well Enzyme solution. - b. Incubate for 5 minutes at room temperature. Incubation starts as soon as the Multidrop Micro starts adding Enzyme Solution. Incubation has ended when the Multidrop 384 starts adding Substrate solution. So the next step is done while the plates are incubating.
- a. Dispense, with the
-
- a. Dispense, with the
Multidrop 384, 25 μL/well Substrate solution. - b. Incubate again for 30 minutes at RT. Again, incubation starts as soon as the Multidrop Micro starts adding Substrate Solution. However, incubation has ended when the Safire2 starts reading the plate. Keep plates stacked with an empty plate on top of the stack to prevent photobleaching and evaporation.
- a. Dispense, with the
-
- In a separate plate, prepare an 11-point, 2× serial dilution of NADH in 0.2% BSA in PBS. Leave one “no NADH” point. Use BSA from the same stock used to make the Enzyme Solution. Start the serial dilution at 100 μM NADH. Dispense 70 μL/well in quadruplicate
-
- CCMPD=NADH concentration measured in a well containing compound
- CNEG=NADH concentration measured in a negative control well (DMSO only)
- CPOS=NADH concentration measured in a positive control well (UDP-xylose)
TABLE 2 |
POC Values |
POC Value | Compound Effect |
<0% | Test compound speeds up the reaction |
=0% | Test compound is not active |
>0% | Test compound is inhibitory |
=100% | Test compound is as inhibitory as is 20 μM |
UDP-glucose | |
>100% | Test compound is more inhibitory than is |
20 μM UDP-glucose | |
TABLE 3 |
Compound Data |
Compound Structure | POC |
|
61% |
|
73% |
|
86% |
|
46% |
|
83% |
|
81% |
|
106% |
|
101% |
|
59% |
|
74% |
|
47% |
|
80% |
|
88% |
|
148% |
|
54% |
|
62% |
|
126% |
|
72% |
|
50% |
|
88% |
|
46% |
|
62% |
|
105% |
|
61% |
|
63% |
|
86% |
|
103% |
|
65% |
|
61% |
|
75% |
|
63% |
|
56% |
|
55% |
|
71% |
|
66% |
|
55% |
|
51% |
|
51% |
|
58% |
|
50% |
|
103% |
|
74% |
|
46% |
|
65% |
|
50% |
|
52% |
|
58% |
|
70% |
|
56% |
|
66% |
|
46% |
|
57% |
|
46% |
|
57% |
|
62% |
|
82% |
|
87% |
|
49% |
|
57% |
|
51% |
|
47% |
|
46% |
|
58% |
|
47% |
|
85% |
|
68% |
|
47% |
|
45% |
|
67% |
|
46% |
|
45% |
|
47% |
|
58% |
|
45% |
|
50% |
|
48% |
|
51% |
|
73% |
|
73% |
|
59% |
|
83% |
|
67% |
|
83% |
|
76% |
|
76% |
|
71% |
|
73% |
|
98% |
|
98% |
|
99% |
|
53% |
|
97% |
|
58% |
|
61% |
|
73% |
|
91% |
|
96% |
|
69% |
|
79% |
|
66% |
TABLE 4 |
Kinetic parameters of WT and mutant UGDH |
UDP-glucose | NAD+ |
Km | VMAX | Km | VMAX | ||
(μM) | (nmol/min/mg) | (μM) | (nmol/min/mg) | ||
WT-UGDH | 48.8 ± 5.5 | 240.9 ± 8.0 | 1031 ± 215 | 206.1 ± 13.0 |
T325A- | 82.2 ± 9.6 | 260.8 ± 9.8 | 1682 ± 455 | 103 ± 8.5 |
UGDH | ||||
T325D- | 25.3 ± 4.0 | 63.1 ± 3.2 | 1203 ± 290 | 38.0 ± 2.5 |
UGDH | ||||
TABLE 5 |
Inhibition Data |
UDP- | Inh # | 5210344 | |
IC50 (μM) | Ki (μM) | IC50 (μM) | Ki (μM) | IC50 (μM) | Ki (μM) | ||
WT-UGDH | 0.58 ± 0.09 | 2.67 ± 0.54 | 260.7 ± 6.2 | ND* | 146.8 ± 1.05 | ND*** |
T325A-UGDH | ND | ND | ND | 421.4 ± 117.6 | 86.98 ± 0.03 | ND |
T325D-UGDH | ND | ND | ND | ND | 799.4 ± 0.05** | ND |
*Inhibitor (1) caused a synergistic product inhibition curve (very high Ki) | ||||||
**Required 4 μM T325D in order to see effect instead of 1 μM | ||||||
***Fit to allosteric sigmoidal curve which led to increased Hill coefficients |
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/136,419 US11478457B2 (en) | 2015-04-23 | 2016-04-22 | Castration-resistant prostate cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562151869P | 2015-04-23 | 2015-04-23 | |
US15/136,419 US11478457B2 (en) | 2015-04-23 | 2016-04-22 | Castration-resistant prostate cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
US20160310528A1 US20160310528A1 (en) | 2016-10-27 |
US11478457B2 true US11478457B2 (en) | 2022-10-25 |
Family
ID=57144296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/136,419 Active 2036-10-11 US11478457B2 (en) | 2015-04-23 | 2016-04-22 | Castration-resistant prostate cancer |
Country Status (2)
Country | Link |
---|---|
US (1) | US11478457B2 (en) |
WO (1) | WO2016172545A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3468546A4 (en) * | 2016-06-09 | 2020-04-01 | Cedars-Sinai Medical Center | Compositions and methods for treating cancer |
EP3728194A4 (en) * | 2017-12-20 | 2021-06-09 | Otago Innovation Limited | Quinoline sulfonamide compounds and their use as antibacterial agents |
CN108997453B (en) * | 2018-07-20 | 2021-01-01 | 四川省中医药科学院 | Diphenyl ethyl ketone glycoside compound and preparation method and application thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040204435A1 (en) * | 2003-04-09 | 2004-10-14 | Joachim Liehr | Alternating treatment with topoisomerase I and topoisomerase II inhibitors |
WO2005019190A2 (en) * | 2003-08-20 | 2005-03-03 | Vertex Pharmaceuticals Incorporated | (4 -amino -1,2, 5-oxadiazol-4-yl) -hetξroaromatic compounds useful as protein kinase inhibitors |
US20080020973A1 (en) * | 2004-08-03 | 2008-01-24 | The Johns Hopkins University | Assays for identification of topoisomerase inhibitors |
US20090291967A1 (en) * | 2008-03-05 | 2009-11-26 | Adherex Technologies, Inc. | Small molecule modulators of cell adhesion |
US20100099683A1 (en) | 2007-04-10 | 2010-04-22 | Tomkinson Alan E | Compounds that inhibit human dna ligases and methods of treating cancer |
US8106037B2 (en) | 2007-08-03 | 2012-01-31 | The Brigham And Women's Hospital, Inc. | Identification and treatment of estrogen responsive prostate tumors |
US20120034250A1 (en) | 2009-04-14 | 2012-02-09 | Astellas Pharma Inc. | Condensed pyrrolopyridine derivative |
US20140011767A1 (en) | 2012-04-19 | 2014-01-09 | Min Yang | Biomarkers to identify patients that will respond to treatment and treating such patients |
-
2016
- 2016-04-22 US US15/136,419 patent/US11478457B2/en active Active
- 2016-04-22 WO PCT/US2016/028936 patent/WO2016172545A1/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040204435A1 (en) * | 2003-04-09 | 2004-10-14 | Joachim Liehr | Alternating treatment with topoisomerase I and topoisomerase II inhibitors |
WO2005019190A2 (en) * | 2003-08-20 | 2005-03-03 | Vertex Pharmaceuticals Incorporated | (4 -amino -1,2, 5-oxadiazol-4-yl) -hetξroaromatic compounds useful as protein kinase inhibitors |
US20080020973A1 (en) * | 2004-08-03 | 2008-01-24 | The Johns Hopkins University | Assays for identification of topoisomerase inhibitors |
US20100099683A1 (en) | 2007-04-10 | 2010-04-22 | Tomkinson Alan E | Compounds that inhibit human dna ligases and methods of treating cancer |
US8106037B2 (en) | 2007-08-03 | 2012-01-31 | The Brigham And Women's Hospital, Inc. | Identification and treatment of estrogen responsive prostate tumors |
US20090291967A1 (en) * | 2008-03-05 | 2009-11-26 | Adherex Technologies, Inc. | Small molecule modulators of cell adhesion |
US20120034250A1 (en) | 2009-04-14 | 2012-02-09 | Astellas Pharma Inc. | Condensed pyrrolopyridine derivative |
US20140011767A1 (en) | 2012-04-19 | 2014-01-09 | Min Yang | Biomarkers to identify patients that will respond to treatment and treating such patients |
Non-Patent Citations (15)
Title |
---|
Batog et al. 2000, vol. 36 No. 1, Chemistry of Heterocyclic Compounds pp. 91-100. * |
Buonerba et al. (Cancer Chemother. Pharmacol. 2011, 67:1455-1461). (Year: 2011). * |
Egger et al. 2010, Biochemical Society Transactions, vol. 38, part 5, pp. 1378-1385 (Year: 2010). * |
Fraser et al., "Hyaluronan: its nature, distribution, functions and turnover," J. Intern. Med., 1997, 242: 27-33. |
Guillemette C., "Pharmacogenomics of human UDP-glucuronosyltransferase enzymes," Pharmacogenomics J., 2003, 3:136-158. |
Huang et al. (Int. J. Cancer, 2010 126(2), 315-327). (Year: 2010). * |
Huang et al., "UDP-glucose dehydrogenase as a novel field-specific candidate biomarker of prostate cancer," International Journal of Cancer, 2010, 126(2), 315-327. |
Hyde et al., "UDP-glucose Dehydrogenase Activity and Optimal Downstream Cellular Function Require Dynamic Reorganization at the Dimer-Dimer Subunit Interfaces," Journal of Biological Chemistry, Dec. 2013, 288(49): 35049-35057. |
International Preliminary Report on Patentability in International Application No. PCT/US2016/028936, dated Oct. 24, 2017, 7 pages. |
International Search Report and Written Opinion in International Application No. PCT/US2016/028936, dated Jul. 27, 2016, 12 pages. |
King et al., "Characterization of Rat and Human UDP-Glucuronosyltransferases Responsible for the in Vitro Glucuronidation of Diclofenac," Toxicol. Sci., 2001, 61(1):49-53. |
Loriot et al. (Annals of Oncology, 20, 2009, pp. 703-708). (Year: 2009). * |
Prydz et al., "Synthesis and sorting of proteoglycans," J. Cell Sci., 2000, 113:193-205. |
Sengupta et al. Indian Journal of Chemistry, vol. 47B, Mar. 2008, pp. 460-462. (Year: 2008). * |
Wei et al., "Androgen-stimulated UDP-glucose dehydrogenase expression limits prostate androgen availability without impacting hyaluronan levels," Cancer Res., Mar. 2009, 69(6): 2332-2339. |
Also Published As
Publication number | Publication date |
---|---|
US20160310528A1 (en) | 2016-10-27 |
WO2016172545A1 (en) | 2016-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11478457B2 (en) | Castration-resistant prostate cancer | |
US20050143578A1 (en) | Compounds and methods | |
US7026336B1 (en) | Compounds | |
US9550759B2 (en) | Nitrocatechol derivatives as COMT inhibitors | |
US8283351B2 (en) | Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof | |
US20060211697A1 (en) | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents | |
US9353121B2 (en) | Anti-cancer compounds targeting Ral GTPases and methods of using the same | |
US10301300B2 (en) | Xanthine oxidase inhibitor | |
US7368467B2 (en) | Ion channel modulators | |
US20050004116A1 (en) | Triazole inhibitors of type 2 methionine aminopeptidase | |
US9388174B2 (en) | Azole benzene derivative | |
US20150004134A1 (en) | Treatment of cancer with heterocyclic inhibitors of glutaminase | |
US20100144733A1 (en) | Compounds, compositions and methods comprising heteroaromatic derivatives | |
US20060264461A1 (en) | Imidazolamino compounds | |
US20090318429A1 (en) | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | |
US20140329796A1 (en) | Heterocyclic amide derivative and pharmaceutical product containing same | |
US20090105254A1 (en) | Vhr protein tyrosine phosphatase inhibitors, compositions and methods of use | |
US7297694B2 (en) | Pyridylfurans and pyrroles as Raf kinase inhibitors | |
US20120094974A1 (en) | Smoothened receptor modulators | |
US20220177459A1 (en) | Aromatic amine compound and use thereof in preparation of ar and brd4 dual inhibitors and regulators | |
US7211576B2 (en) | Diaminothiazoles | |
WO2003051906A2 (en) | Compounds and methods | |
US20060019971A1 (en) | Treatment of cardiovascular disease with inhibitors of p38 kinase | |
US9376402B2 (en) | 1, 2, 4-triazole derivatives and their anti-microbial activity | |
US20140371259A1 (en) | Compounds and methods for inhibition of ap endonuclease-1/redox factor-1 (hape1) activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA, NEBRASKA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SIMPSON, MELANIE A.;BARYCKI, JOSEPH;REEL/FRAME:038713/0949 Effective date: 20160428 Owner name: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA, NE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SIMPSON, MELANIE A.;BARYCKI, JOSEPH;REEL/FRAME:038713/0949 Effective date: 20160428 |
|
AS | Assignment |
Owner name: NUTECH VENTURES, NEBRASKA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA;REEL/FRAME:039623/0348 Effective date: 20160901 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction |